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SUMMARY 
Hypertension is a frequently occurring disease of the developed as well as the 
developing countries. Although a persistent elevation of blood pressure beyond the 
normal range may be devoid of clinical symptoms but the complications resulting from 
this disorder are severe. Peripheral vascular resistance, vascular reactivity, cardiac 
output, the autonomic nervous control, blood viscosity etc. may all be involved in a very 
complex and interdependent manner. 
The life span of hypertensive patients can be increased by many years if 
appropriate therapeutic measures bring about a reduction in blood pressure to near 
normal level. The main thrust of antihypertensive therapy consists of treatment with 
drugs. Usually the treatment is symptomatic regardless of the type of hypertension. 
However, the cause should be treated as soon as possible, for which, reasonable 
knowledge of the cause of hypertensive disease and the mechanism of action of 
antihypertensive drugs is important. Many potential sites and mechanisms exist through 
which a drug may exert its antihypertensive effect. 
The first attempt at modern pharmacotherapy of hypertension began around 
1955 with the availability of drugs like reserpine, hydralazine, veratrum alkaloids, thiazide 
diuretics and guanethidine. Although, these drugs made the first real impact on the 
morbidity and mortality associated with the complications of hypertension, the side 
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effects of these agents remained unacceptable to many patients. As a result some of 
these compounds were, discarded or had to be used in combination with other drugs. 
Attention was subsequently drawn towards the influence of the central nervous system 
In the development of hypertensive disease. Thus clonidine was developed, which 
decreased blood pressure by acting mainly on the central nervous system. The brain 
stem has been shown to be an important site of action. 
The etiology of primary hypertension is obscure and hence the choice of drug 
treatment cannot be wholly adequate. Moreover, the pharmacotherapy remains the most 
useful tool in the management of primary hypertension. The treatment has to be often 
life long and a high standard of efficacy and safety is required of the drugs used. The 
antihypertensive drugs can be mainly classified as (1) centrally acting antihypertensives, 
mainly adrenergic agonists -(2) peripherally acting antihypertensives, which can be 
antiadrenergic, mineralocorticoids, diuretics and direct acting drugs. We have selected 
clonidine a centrally acting drug, hydralazine a peripherally acting antihypertensive, 
reserpine which acts by releasing catecholamines and centhaquin a new centrally 
acting antihypertensive drug. 
1. Radioreceptor binding studies: Two types of binding sites exist, one which is specific 
to the type of receptor under investigation and the other is nonspecific binding to the 
biopolymers of the tissue. Since the number of specific receptors sites are limited, and 
the nonspecific sites are unlimited, the binding experiment was repeated in the 
presence of excess amount of non-radiolabelled ligand. Tpi^^^AB J[gands^ ^used for 
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radioreceptor binding to different neurotransmitter receptors are as follows: 
Receptor 
a-adrenergic 
B-adrenergic 
Muscarinic 
Dopamine 
5-hydroxytry-
ptamine 
(5HTJ 
5-hydroxytr-
yptamincg 
(5HT2) 
Hot ligand 
^H-Dihydroergocryptine 
0.25-12 nM (Amersham) 
^H-Dihydroalprenolol 
0.12-4 nM (Amersham) 
^H-Quinuclidinyl 
benzylate 0.1-2 nM (NEN) 
^H-Spiperone 
0.1-5 nM (NEN) 
^H-5-hydroxytryptamine 
0.25-15 nM (NEN) 
^H-Spiperone 
0.15-10 nM (NEN) 
Cold ligand 
Phentolamine 
(1 MM) 
Propranolol 
(1 MM) 
Atropine 
(1 MM) 
Haloperidol 
(1 ;:M) 
5-hydroxytry-
ptamine(5-HT) 
(1 MM) 
Ketanserin 
(1 MM) 
Radioreceptor binding studies were carried out with these ligands for the specific 
receptors in corpus striatum, cortex, hypothalamus and medullary regions of the rat 
brain. The changes in receptor affinity and density was studied. 
2. Effects of centhaquin on blood pressure and heart rate in normal and cervical 
sectioned rats was recorded on a Grass Model 7 Polygraph. 
3. Microinjection studies were performed in cats by placing a cannula in the nucleus 
tractus solitarius (NTS). Drugs like centhaquin, clonidine, phentolamine, yohimbine and 
prazosin were injected by the help of a microsyringe. 
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4. Studies on thermoregulation and blood pressure. Rats were cannulated at the lateral 
cerebral ventricle (icv) and allowed to recover. Then they were chronically treated with 
the oral administration of four antihypertensive drugs selected in this study. The rats 
were then tested for their responses to noradrenaline, dopamine, acetylcholine and 5-
HT. Temperature measurements were done by measuring the core temperature of the 
albino rats with a thermistor probe inserted 2 cm into the rectum and connected to a 
programmed apple computer. The temperature was recorded before the drug 
administration and immediately after it at regular intervals of 10 minutes for 5 hours. 
Blood pressure was recorded by the IITC in 6 instrument which measures.the systolic 
as well as the mean blood pressure. The blood pressure before administration of the 
drug was compared to the change in blood pressure after the drug injection. • 
Till now, not much attention has been given to the status of central 
neurotransmitter receptors in hypertension, and the effect of antihypertensive drugs on 
central neurotransmitter receptors. It was thought that if, antihypertensive drugs, like 
centhaquin, donidine (which are centrally, acting), hydralazine (which acts through a 
peripheral mechanism) and reserpine (which has a complex mechanism of action, but 
mainly peripheral) are administered chronically, they are likely to produce different 
actions on various central neurotransmitter receptors. Broadly centrally acting 
antihypertensives will have direct effect on the CNS receptors, while peripherally acting 
antihypertensives are not likely to produce any change in central receptors. If 
peripherally acting antihypertensives do produce alteration in central receptors, it could 
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be due to a secondary (feedback) effect i.e. due to " decreased blood pressure the 
central receptors are altered. Since medulla and hypothalamus are the main areas of 
brain involved in blood pressure regulation, alteration of receptor characteristics in these 
areas will be of direct relevance to regulation of blood pressure. Other brain regions 
like striatum and cortex are less involved in cardiovascular regulation. 
Receptor binding studies show that clonidine and centhaquin increase both the 
affinity and density of o-adrenoceptors in hypothalamus and medulla of rat brain, while 
peripherally acting antihypertensive drugs, hydralazine and reserpine decrease the 
density of a-adrenoceptors in all four brain regions. Since the affinity of clonidine for 
presynaptic o-adrenoceptors is at least ten times higher than its affinity for postsynaptic 
a-adrenoceptors, it could be possible that repeated administration of clonidine 
decreases the release of norepinephrine in hypothalamus and medulla by acting on 
presynaptic receptors. Thus the decreased concentration of norepinephrine in the 
synapse will result in increase in the density of post synaptic a-adrenoceptors, as 
observed in the present study. The mean blood pressure response to noradrenaline in 
hydralazine and reserpine treated rats was similar to the control rats, while it was 
opposite in clonidine and centhaquin treated rats. This shows a clear differentiation 
between responses of noradrenaline in centrally and peripherally acting 
antihypertensive drugs and also strengthens our contention that besides clonidine, 
centhaquin a newly developed antihypertensive drug acts on central adrenergic 
receptors, which in all probability could be a adrenergic receptors. Centhaquin and 
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clonidine did not affect the density or affinity of- B adrenergic receptors. Further 
supporting the fact that 3 adrenergic receptors are not involved in the action of centrally 
acting antihypertensive drugs. In the present study both biochemical and 
pharmacological evidences have been provided indicating an alteration in central 
adrenergic receptors. 
In hypothalamus and medulla clonidine and centhaquin did not affect either the 
density or the affinity of ^H-spiperone binding. Some non specific changes was 
observed in hydralazine and reserpine treated rats. Dopamine (50 ^g. ICV) produced 
no significant change in either colonic temperature or mean blood pressure in control, 
clonidine and reserpine treated rats. In hydralazine treated rats a significant decrease 
in blood pressure and increase in colonic temperature were observed. In centhaquin 
treated rat no change in blend pressure occurred, however a significant increase in colonic 
temperature was observed. It is clear from the above results which provide both 
biochemical and pharmacological evidence that central dopaminergic receptors are not 
involved in blood pressure regulation or in the action of centrally acting antihypertensive 
drugs. 
• Centhaquin treatment produced no change in the density and affinity of ^H-
quinuclidinyl benzylate binding. Clonidine treatment produced a decrease in the density 
and affinity of the muscarinic receptors. No change was observed in the density and 
affinity of the muscarinic receptors by hydralazine and reserpine treatment. Acetylcholine 
(10 Mg, ICV) produced a decrease in colonic temperature in control rats. Peripherally 
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acting antihypertensive drugs, hydralazine and reserpine treated rats showed no change 
in colonic temperature. Centrally acting antihypertensive drug, centhaquin treated rats 
showed a decrease in colonic temperature, as-control-Fats. However, clonidine treated 
rats showed a significant increase in colonic temperature in response to acetylcholine. 
Blood pressure was decreased by acetylcholine (10 HQ, ICV) in control rats as well as 
in centhaquin, hydralazine and reserpine treated rats. However clonidine treated rats 
showed a significantly greater decrease in blood pressure in comparison to other 
groups of rats. These results indicate that clonidine does act on cholinergic receptors 
and might be producing s o m e ^ antihypertensive effect through these receptors. 
The evidences for the involvement of serotonergic system in the regulation of 
blood pressure are very strong. These results of the present study indicate both 
biochemically and pharmacologically that 5-HT receptors of the brain might be involved 
in the action of centrally acting antihypertensive drugs. 
Centhaquin when administered intravenously produced hypotension and 
bradycardia in normal rats. In cervical sectioned rats it did not produce any effect on 
blood pressure or heart rate. This suggests that centhaquin produces hypotension and 
bradycardia by acting directly in the central nervous system. Centhaquin given 
intrathecally did not produce any effect on blood pressure and heart rate. This showed 
that the site of action of centhaquin was above the spinal cord. 
Microinjection of centhaquin in the NTS produced mainly bradycardia with little 
effect on blood pressure. In order to determine the nature of receptors involved several 
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^ 
antagonists were administered prior to the administration of centhaquin. It was found 
that phentolamine, which blocl<s both <»^  and «2 adrenergic receptors could block the 
effect of centhaquin. In order to determine which subtype of receptor is involved a, 
adrenergic receptor antagonist prazosin was given prior to the administration of 
centhaquin. The effect of centhaquin was blocked by prazosin. Similarly aj adrenergic 
receptor antagonist yohimbine blocked the effect of centhaquin. It became difficult to 
comment which subtype of receptor is involved. It could be possible that in NTS the 
a adrenergic receptors are of undifferentiated type and are responsive to both prazosin 
and yohimbine. 
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INTRODUCTION 
Arterial hypertension, is a frequently occurring disease all over the world. 
Although persistent elevation of blood pressure beyond the normal range may be 
devoid of clinical symptoms but the complications resulting from this disorder are 
severe. The life span of hypertensive patients can be increased by many years if 
appropriate therapeutic measures bring about a reduction in blood pressure to near 
normal level (Abrams, 1974). The treatment of arterial hypertension is based mainly on 
the administration of drugs lowering blood pressure, although other types of 
interventions like dietary reduction of sodium, normalization of body weight and in 
special conditions surgical intervention has been done. Before 1950 virtually no drug 
therapy was available for the treatment of hypertension. Ganglion blocking agents and 
a-adrenergic blockers were the first group of compounds used to lower pathologically 
elevated blood pressure. Inspite of numerous side effects and disadvantages, these 
compounds made the first real impact on the morbidity and mortality associated with 
the complications of hypertension. Since then, various groups of effective 
antihypertensive drugs with less side effects have been introduced into current therapy. 
The mode of action and the mechanism of side effects of most but not all types of 
antihypertensive drugs is reasonably well understood. However, the most frequently 
occurring type of hypertension is the essential hypertension. Lack of knowledge of 
essential hypertension prevents a complete understanding of the influence of the drug 
on the hypertensive patient. Several of the newer antihypertensive drugs have proved 
to be most useful in elucidating the mechanisms involved in the regulation of blood 
pressure. 
Antihypertensive agents discovered in the early stages of the development of 
such drugs, may exert a part of their effect by acting through the central 
nervous system. A centrally mediated hypotensive effect of hydralazine was 
reported by ingenito et al. CI 969). Although Dontas (1957) showed that 
intravenous injection of the hydralazine did not reduce splanchnic nerve activity, others 
concluded that the action of hydralazine was primarily peripheral (Reis and Van Zwieten, 
1967). Hydralazine dilates arterial resistance vessels more than venous capacitance 
vessels. Thus venous return and cardiac output are increased. Effect on cardiac output 
is further accentuated due to increase in heart rate and myocardial contractility resulting 
from the autonomic reflex response to lowered blood pressure. 
The influence of reserpine on the peripheral sympathetic nervous system is well 
known. The granular stores of noradrenaline are disrupted leading to its enzymatic 
degradation and finally to its depletion. The diminished amount of transmitter substance 
is believed to impair the function of the peripheral sympathetic system thus causing a 
fall in blood pressure. However the extra -granular stores of noradrenaline are hardly 
affected by reserpine, so that this part of the transmitter store remains available (Van 
Zwieten, 1973). 
Hypertension is dependent on many factors which are not fully defined. It is 
generally accepted that the antihypertensive drugs reduce peripheral sympathetic tone, 
so that a decrease in arterial pressure results. The role of the autonomic nervous 
system in causing or sustaining hypertension has been extensively studied (Hilton and 
Spyer, 1980). There are many factors that can influence the activity of the autonomic 
nervous system. The neurotransmitter released from nerve terminals evokes a response 
by acting on specific receptor sites. The magnitude of the response is mainly 
dependent upon the concentration of neurotransmitter and the affinity and population 
of these receptors. Several neurotransmitters like adrenergic, cholinergic, dopaminergic, 
serotonergic, opioidergic, GABAergic etc have been reported to play a role in the 
regulation of the cardiovascular system and a change in function of one or more of 
them may lead to hypertension. 
Until recently most studies have been confined to the processes of 
neurotransmitter synthesis, the frequency of nerve impulses, the process of release of 
neurotransmitter and its inactivation by uptake mechanism or enzymatic degradation 
or both. Very little attention has been paid to the status of neurotransmitter receptors 
in the brain of hypertensive subjects. With the increasing use of ligand binding studies 
it is possible to precisely determine the type of receptors along with their affinity and 
density in any particular area of the brain. 
Studies have been carried out using the radioligand binding technique to 
determine the difference in the receptor affinity and population between control and 
hypertensive rats. It is known that the number of central neurotransmitter receptors alter 
in an inverse manner to changes in the neuronal activity (Skolnick et al., 1978; 
U'Pritchard et al., 1979; 1980; Morris et al., 1980). It is expected that a change in 
receptors will also reflect the neuronal activity. Most studies have reported an increase 
in the population of central «^  and cig adrenoceptors (Gheyouche et al., 1980; Morris 
et al., 1981; Palmero et al., 1981; Wirz-Justice et al., 1983) while some have reported 
no change In a adrenoceptors (Hellstrand and Engel, 1980; Cantor et al., 1981) in 
spontaneously hypertensive rats (SHR). The a adrenoceptors located in the nucleus 
tractus solitarius (NTS), responsible for the facilitation of transmission of baroreceptor 
impulses, are of the aj type. Evidence has also been found that o, adrenoceptors in 
NTS have opposite effects (Anden et al., 1978; Mouille et al., 1980; Persson et al., 1981; 
Huchet et al., 1981; 1982). Increase in the population of central a^ adrenoceptors in 
spontaneous'^^lypertensive rats may thus be expected to oppose the cardio-inhibitory 
response to centrally acting sympathomimetics that possibly accompany increase in 
density of oj adrenoceptors. On the other hand, a adrenoceptor binding has been 
reported to be both decreased (Myers et al., 1981) and increased (Wirz-Justice et a!., 
1983). Observations by Bottiglieri et al. (1988) suggest that increase in a adrenoceptor 
may be the result of their increased synthesis or decreased degradation. The functional 
role of 3 adrenoceptors is not clear. 
Central dopaminergic system also plays a role in hypertension (Yen et al., 1979; 
Martin and Quock, 1980; Bhargava, 1983). Evidence of increased [^H]-spiroperidol 
binding has been obtained in SHR rats (Chiu et al., 1982; Bhargava, 1984). Since, it has 
been reported that stimulation of central dopaminergic system also results in the 
inhibition of noradrenergic system (Maj et al., 1970; Seeman, 1980), it could be possible 
that the prolonged decrease in brain dopaminergic activity in hypertensive subjects 
leads to the development of dopamine receptor supersensitivity and an increase in o, 
and aj adrenoceptor population. 
Serotonergic mechanisms in the brain have been suggested to affect blood 
pressure but the results are controversial (Antonaccio 1984). There are multiple 
interactions between the central serotonergic system and sympathetic system with 
respect to cardiovascular control but their nature is not well understood. 
The role of brain acetylcholine in cardiovascular regulation has been considered 
but not well investigated. Recent work strongly suggests that it may have a role in 
modulating baroreceptor reflexes and in elevating arterial pressure through increased 
sympathetic activity (Brezenoff and Coram, 1982). 
It is apparent from the available literature that even though a lot of work has 
been done on the physiological aspect of neurotransmitters but not much has been 
done to study the influence of repeated administration of antihypertensive drugs on 
centra! neurotransmitter receptors. It is important to determine the status of central 
receptors in animals treated chronically with antihypertensive drugs. The effect of 
antihypertensive drugs on these receptors will ultimately define the role of these 
receptors in the antihypertensive action of these drugs and in hypertension. 
REVIEW OF LITERATURE 
Hypertension is a frequently occurring disease erf the developed as well as the 
developing countries. Although a persistent elevation of blood pressure beyond the 
normal range may be devoid of clinical symptoms but the complications resulting from 
this disorder are severe. The genesis of hypertensive disease is complex where many 
different factors may be involved. Peripheral vascular resistance, vascular reactivity, 
cardiac output, the ai^ itonomic nervous control, blood viscosity etc. may all be involved 
in a very complex and interdependent manner. 
The life span of hypertensive patients can be increased by many years if 
appropriate therapeutic measures bring about a reduction in blood pressure to near 
normal level (Abrams 1974). The main thrust of antihypertensive therapy consists of 
treatment with drugs. Usually the treatment is symptomatic regardless of the type of 
hypertension. However as quickly as passible the cause should be treated. For this, 
reasonable knowledge of the cause of hypertensive disease and the mechanism of 
action of antihypertensive drugs is important. Many potential sites and mechanisms exist 
through which a drug may exert its antihypertensive effect. The first attempt at modern 
pharmacotherapy of hypertension began around 1955 with the availability of drugs like 
reserpine, hydralazine, veratrum alkaloids, thiazide diuretics and guanethidine. Although, 
these drugs made the first real impact on the morbidity and mortality associated with 
the complications of hypertension, the side effects of these agents remained 
unacceptable to many patients. As a result some of these compounds were discarded 
or had to be used in combination with other drugs. Attention was subsequently drawn 
towards the influence of the central nervous system in the development of hypertensive 
disease. Clonidine (Catapres 155) was developed, which decreased blood pressure 
by acting mainly on the central nervous system. The brain stem has been shown to be 
an important site of action of this agent (Schmitt et al., 1968). Reduction of central 
sympathetic outflow also contributes to the fall in blood pressure produced by this drug 
and guanabenz (Baun and Shropshire, 1970). 
The etiology of primary hypertension is obscure and hence the choice of drug 
treatment cannot be wholly adequate. Moreover, the pharmacotherapy remains the most 
useful tool in the management of primary hypertension. The treatment has to be often 
life long and a high standard of efficacy and safety is required of the drugs used. The 
antihypertensive drugs can be mainly classified as (1) centrally acting antihypertensives, 
mainly adrenergic agonists (2) peripherally acting antihypertensives, which can be 
antiadrenergic, mineralocorticoids, diuretics and direct acting drugs. We have selected 
clonidine a centrally acting drug, hydralazine a peripherally acting antihypertensive, 
reserpine which acts by releasing catecholamines and centhaquin a new centrally 
acting antihypertensive drug for study. 
CENTHAQUIN 
Centhaquin is an antihypertensive drug developed at the Central Drug Research 
Institute, Lucknow, India. It is a synthetic, white crystalline compound with poor solubility 
in water but is soluble in ethanol and propylene glycol. The pharmacological profile of 
centhaquin shows hypotensive activity in different models of hypertension. It decreases 
cardiac output and causes a slight increase in mesenteric blood flow and femoral blood 
flow showing a little bit of vasodilation. It is a weak central nervous system depressant 
at the dose at which a hypotensive effect is obtained. Centhaquin shows reasonably 
good diuretic activity and a wide margin of safety with high LD50 values. The marked 
hypotensive effect of the compound is retained in decerebrate cats. A small dose of 5 
microgram given in the vertebral artery shows a significant fall in blood pressure. The 
effect of centhaquin on pre and post ganglionic sympathetic nerve stimulation of 
nictitating membrane is very minimal. The intravenous administration of centhaquin to 
spinal cat produced a much reduced effect compared to decerebrate unanesthetized 
cat ( Raghubir et al., 1987). Thus centhaquin was found to be a 
centrally acting antihypertensive agent. The site and mechanism of action of centhaquin 
are yet to be determined. The nature of neurotransmitters involved in action of 
centhaquin was also to be determined. Toxicity studies showed this compound to be 
safe and there was no histopathological, biochemical or physiological abnormality 
observed after repeated" administration of centhaquin in rats, mice or monkeys. The 
major side effect of centrally acting antihypertensive drugs is sedation and drowsiness. 
In rats, centhaquin produced a dose dependent decrease in spontaneous motor activity. 
Doses above 120 mg/kg i.p. produced ataxia, decreased respiration and hypothermia. 
CLONIDINE 
Clonidine, 2(2,6-dichlorophenylamino)2-imidazoIine, also called ST 155 or 
Catapresan or Catapres or Catapressan, was synthesized by Stahle in 1962. It was 
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originally developed as a nasal decongestant but during clinical trials clonidine was 
found to produce bradycardia, hypotension and sedation. Experiments by Graubner and 
Wolf (1966) confirmed these findings and clonidine was introduced in the clinical 
practice as an antihypertensive drug. 
Clonidine exerts a complex action on the circulation when administered 
intravenously, it induces biphasic changes in blood pressure, initial hypertension 
followed by a long lasting hypotensive effect. As the dosage is increased, the intensity 
and duration of the hypertensive effect becomes greater and hypotension is delayed. 
In addition.bradycardia and reduction in cardiac output are constant features in animal 
and man. The initial increase in blood pressure has been suggested to be secondary 
to vasoconstriction as a result of direct activation of « adrenoceptors, since clonidine 
is effective following pretreatment with reserpine (Hoefke and Kobinger, 1967), 
guanethidine (Raz2al< et al., 1975) and bretylium. This a adrenergic 
effect can be blocked by a adrenoceptor antagonists such as phentoiamine and 
phenoxybenzamine (Boissier et al., 1968; Constantine and McShane, 1968; Schmitt and 
Schmitt, 1970). The hypotensive action is caused by a centrally mediated reduction in 
peripheral sympathetic tone through stimulation of central a adrenoceptors (Anden et 
a!., 1970; Bock and Van Zwieten, 1971; Haeusler, 1974; Kobinger and Pichler, 1974; 
Finch et al., 1975; Van Zwieten, 1975) Other possible mechanisms suggested include 
stimulation of central Hj-receptors (Karppanen et al., 1976); involvement of central 
cholinergic mechanism (Srimal et al., 1977) and central opioid mechanism (Raghubir et 
al., 1985). Investigations with spinal animals revealed only increase in blood pressure 
that was even more distinct than in intact animals (Constantine and McShane, 1968; 
Kobinger and Walland, 1967a). Administration of clonidine (1 (.g/kg) into the cisterna 
cerebellomedullaris of cat caused a long lasting fall in blood pressure and bradycardia, 
whereas intravenous injection of the same dose was largely ineffective (Kobinger, 
1967; Schmitt et a!., 1968). Low concentrations of clonidine infused into one of the 
vertebral arteries caused a fall in blood pressure and bradycardia, whereas hardly any 
effect was observed following infusion of the same doses into a peripheral vein (Sattler 
and Van Zwieten 1967). Clonidine injected intracerebroventricularly (icv) in dogs, cats 
and rabbits induced a decrease in blood pressure (Sherman et al., 1968; Schmitt, 1969) 
According to Haeusler (1982) ag adrenoceptors in the nucleus tractus solitarius 
(NTS) are the main site of action of clonidine. Infusion of clonidine into the NTS reduced 
blood pressure and heart rate (Sinha et a!., 1975). Therefore, this area is considered 
to be the main site of action. However, lesions of this area did not change blood 
pressure in cat (Antonaccio and Halley, 1976; Laubie et al., 1976), and clonidine 
continued to reduce blood pressure and heart rate. A small area on the ventral surface 
of the medulla of cats (Schaffe's zone) seems to be another site of action of clonidine. 
Bousquet and Guertzenstein (1973) were able to block the cardiovascular actions of 
clonidine administration locally in this area with pimozide, thus supporting a 
dopaminergic action, but piperoxan was also an effective antagonist. Microinjection of 
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clonidine into the nucleus reticularis lateralis in cats also lead to hypertension and 
bradycardia (Bousquet et al., 1981 ). Franz and Madsen (1982) suggested that 
although the spinal reflex pathway was more sensitive to depression by clonidine than 
its different descending intraspinal pathway, analysis of the relative depression of 
transmission at spinal and at brainstem level indicate that the spinal site is more 
sensitive to clonidine -than was considered. The bradycardiac effect is mainly brought 
about by facilitation of vagal reflex activity (Van Zwieten, 1975). 
In the periphery, clonidine has been proposed to interact with presynaptic a 
adrenoceptors in the arterial wall and the effect on the cardiac pacemaker seems to be 
due to stimulation of a adrenoceptors in adrenergic nerve endings and thus reduction 
of transmitter release (Starke and Altmann, 1973; Langer, 1977). Kupfer et al. (1980) 
have reported that the effect of clonidine (0.003 mg/kg, intracisternally) was reversed 
when the drug was given after the alkaloid. These results suggest possible interactions 
of the drugs at central GABAergic, glycinergic or cholinergic synapses. 
Since the effects of noradrenaline are potentiated after clonidine in pithed rats 
(Boissier et al., 1968) some peripheral component must be involved. In man, no 
significant interaction of clonidine with catecholamines was observed (Onesti et al., 
1971). In high doses, clonidine reduced the effect of noradrenaline (Boissier et a!., 
1968). However, Reinhard and Roth (1982) reported that clonidine administration (30 
iiQ/kg) did not alter the levels of noradrenaline, serotonin, dopamine, homovanallic acid 
or 3,4,-dihydroxyphenylacetic acid in the brain. Coupar and Kirby (1972) suggested that 
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clonidine may cause venodilation by blocking endogenous release of noradrenaline, an 
effect which may contribute to the hypotensive action of the drug. Experiments by 
Anglade et al (1987) demonstrated that clonidine decreases adrenaline release from the 
adrenal glands through a central and not a peripheral mechanism in dogs, and this 
action might contribute to its antihypertensive effect. 
The concept .that a presynaptic a adrenoceptor stimulation could inhibit 
noradrenaline release is generally accepted (Starke et al., 1975). Phentolamine increases 
noradrenaline release and in addition antagonizes the effect of clonidine (Starke et al., 
1974). Greenberg and Wilborn (1982) suggested that clonidine may act on the veins 
or indirectly by inhibiting the release or synthesis of a trophic noradrenergic factor, to 
reverse the functional and structural changes in the veins. It has been proposed by 
Lorez et al. (1983) that the effect of clonidine on noradrenaline turnover is most likely 
the result of a local feedback inhibition through presynaptic o adrenoceptors. Medgett 
and Rand (1983) suggested that the NTS and intermediolateral cell column of the spinal 
cord are the prime centers for the cardiovascular action of clonidine. Since the 
cardiovascular effects of clonidine can be elicited in the virtual absence of neuronal 
noradrenaline, the decrease in central noradrenaline turnover and the cardiovascular 
effects of clonidine are not interrelated phenomena. Observations by Schoener and Pitts 
(1985) suggested that the dose related depression of mean arterial pressure and heart 
rate under basal conditions may be related to specific oj adrenoceptor activation of the 
NTS. Bentley et al. (1986) proposed that clonidine causes a selective reduction in 
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sympathetic tone to the veins that is mediated atleast partly by a central action as well 
as an expansion of the collateral venous routes. This together with the selective 
impairment of venoconstrictor responses to both noradrenaline and adrenaline, may 
account for the decrease in cardiac output that is most often reported following 
clonidine induced reduction of mean arterial pressure. Clonidine given peripherally or 
centrally to normal or spontaneously hypertensive rats is associated with development 
of tolerance or tachyphylaxis to its cardiovascular response (Mastrianni and Ingenito 
1985). 
In dogs, intrarenal arterial administration of clonidine not only decreased renal 
blood flow (RBF) without affecting glomerular filtration (GFR) but increased blood 
pressure, while intravenous administration decreased RBF without affecting either GFR 
or blood pressure. This may be explained by the fact that clonidine acts predominantly 
at post synaptic and central sites in the latter instance (Chrysant and Lavender, 1975). 
However, human studies have shown that neither acute nor chronic oral clonidine 
disturbs RBF and may decrease renal vascular resistance (RVR) in hypertensive patients 
(Cohen et al., 1969). 
Clonidine in hypertensive patients reduced the excretion of urinary 
catecholamines (Hokfelt et al., 1975). This effect is believed to be due to the decreased 
sympathetic tone. Clonidine does not change the level of catecholamines in the brain 
(Hoefke and Kobinger, 1966; Persson and Waldeck, 1970; Bralet and Rochett, 1973). 
A slight increase in noradrenaline or dopamine levels has been reported after high 
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doses of clonidine. The increased dopamine level in the corpus striatum could account 
for the stereotypy seen with high doses of the drug (Persson and Waldeck, 1970). On 
the contrary Anden and Grabowska (1976) have reported that clonidine produced only 
a slight decrease of dopamine synthesis and utilization in the striatum. Clonidine has 
no effect on the firing rate of substantia nigra dopamine neurons. 
It did not effect the firing rate of the single substantia nigra dopamine 
neurons, but it regularized the firing pattern and decreased the burst firing at 2-8 ^g/kg, 
i.v. These effects were antagonized by og adrenoceptor antagonist yohimbine (Grenhoff 
and Sevensson,1988). 
It has been further suggested that the bradycardiac effect of clonidine results 
from activation of both central and peripheral og adrenoceptors (Park et al, 1983). 
Chronic administration of the type-A MAO inhibitor, clorgyline, attenuated the central 
responses to clonidine through the reduction in sensitivity of brain a adrenoceptors. 
Pargyline that preferentially inhibits type-B MAO, reduces only the bradycardia induced 
by clonidine. This indicates a different modulation of the receptors involved in this 
responses of clonidine. Clonidine also inhibits locus coeruleus (LC) neurones by 
stimulating aj adrenoceptors (Lai and Fielding, 1983). Neurotransmitter concentration 
in the synaptic cleft may be responsible for the transynaptic population. The aj 
adrenoceptors which are presynaptically located on the serotonergic terminals but are 
postsynaptic in relation to the noradrenergic neurons also show increased sensitivity 
after chronic clonidine treatment (Cerrito et al., 1984). Kawasaki and Takasaki (1985) 
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suggested that clonidine produces hypertension which is mediated by stimulation of 
central postsynaptic oj adrenoceptors. Ketlar et al. (1984) have shown by receptor 
binding studies in the rat cerebral cortex that clonidine is 1,000 times more potent in 
competing for og than for a^ adrenoceptor sites. Stone and Forster (1986) showed that 
['H]-clonidine binding was enhanced in vas deferens and it was unchanged or slightly 
increased in cerebral,brain tissue of rat.[^H]-clonidine binds at particulate membrane 
fractions of human prefrontal cortex, binding showed at least two affinity states (Carlson 
and Andorn, 1986). Treatment of rat cerebral cortex membranes with 10 mM [(3-
cholanidopropyl)-dimethylammenio] 1-propane sulfonate (CHAPSO) solubilized about 
30% [^H]-clonidine binding sites in the starting membranes and showed a nonlinear 
curve, indicating the existence of two distinct binding components (Kitamu a et al., 
1986). Pharmacological evidence suggests that central aj adrenoceptor activation is 
associated with sedation in addition to reduction in blood pressure (Bousquet et al., 
1983). 
Clonidine in a single dose caused a significant fall in blood pressure and heart 
rate. These effects were much more pronounced in SHR - while 
being ineffective in normotensive Wistar Kyoto controls (WKY) (Head and De Jong, 
1986). Prolonged treatment of SHR with clonidine decreased the mean arterial pressure 
and heart rate (Pegram et al., 1982). On stopping chronic clonidine treatment, an abrupt 
rebound of the blood pressure to values higher than those recorded before treatment 
has been reported by several authors. Repeated treatment with clonidine induces a 
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functional subsensitivity of central 02 adrenoceptors. This subsensitivity is mainly 
manifested as attenuation of different effect such as hypothermia (Von Voigtiander et 
al., 1978; Gorka and Zacny, 1981; Pile and Vetulani 1982a,b). 
Chronic clonidine administration can induce down regulation of not only oj 
presynaptic autoreceptors located on noradrenaline terminals but also ag presynaptic 
heteroreceptors located on serotonergic terminals (Maura et al., 1985). The increased 
pressor responsiveness of both SHR and WKY rats to arginine vasopressin following 
clonidine is an unexpected finding and may be related to peripheral interaction between 
a adrenoceptor agonist and vasopressin (Datar et al., 1986). Finberg and Kopin (1987) 
have reported against desensitization of peripheral presynaptic aj adrenoceptors by 
chronic administration of aj adrenoceptor agonist. Sympathetic hyperactivity following 
withdrawal of chronic clonidine treatment may be mediated by down regulation of 
postsynaptic 02 adrenoceptors in the central nervous system. 
Srimal et al. (1977) suggested that an intact cholinergic link in the brain stem is 
essential for the hypotensive action of clonidine. In view of demonstrated interaction 
between clonidine and cholinergic mechanism in some parts of central nervous system 
(Buccafuso and Spector 1980; Buccafuso et al., 1980; Svesson and Engberg 1980)^  
It is possible that clonidine may express at least a part of its antagonistic action on the 
carotid arterial occlusion reflex (CAOR) via inhibition of an excitatory cholinergic 
mechanism in the posterior hypothalamus. Buccafuso et al. (1980) have reported that 
clonidine significantly reduced turnover of acetylcholine from certain brain regions and 
16 
markedly inhibited the pressor response to intravenous administration of physostigmine. 
Criscione et al. (1983) have proposed that cholinergic mechanism in the NTS tends 
tonically to lower arterial pressure after clonidine administration and may modulate the 
baroreceptor reflex without being an integral part of the reflex arc. 
Opioid peptides inhibit locus coeruleus neurons by a direct action at post 
synaptic sites which rpay be related to increase permeability to one or more ions such 
as Cr or K*. They cause a stereospecific hyperpolarization of the neuronal membrane 
which entails an increase in membrane conductance. This effect is reversible by the 
narcotic antagonist naloxone but not by antagonists of other neurotransmitters, including 
02 adrenergic antagonists (Pepper and Henderson 1980). Due to the fact that naloxone 
blocked elevation of blood pressure, cardiac output and heart rate in cats, it is evident 
that the opioid link is present in clonidine induced bradycardia and hypotension 
(Val'dman et al., 1982; Farsang and Kunos, 1979; Kunos et al., 1987). It was concluded 
by Chauhan et al. (1983) that the hypertensive effect could be due to an opioidergic 
mechanism since it was blocked by both naloxone and yohimbine. Although Eriksson 
and Tuomisto (1983) suggested that opioid mechanism possibly participates in the 
hypotensive action of clonidine, but its role is less in normotensive than in 
spontaneously hypertensive animals. In patients of essential hypertension the 
antihypertensive effect of clonidine could be antagonized by the opioid receptor blocker 
naloxone. Plasma concentrations or the opioid peptides 3-endorphin and Leucine 
enkephalin which are lower in young hypertensive patients are normalized by stimulation 
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of «2 adrenoceptors with clonidine (Kraft and Stumpe, 1987). Findings of Kunos et al. 
(1987) Indicate that B-endorphin released from an arcuate NTS pathway acting on 
opiate receptors in the NTS contributes to the cardiovascular depressor effects of 
clonidine. 
HYDRALAZINE 
Hydralazine (1 -hydrazine phthalazine) has been used in the therapy of 
hypertension for about four decades. The hypotensive effect of hydralazine, which is 
characterized by its gradual onset, limited degree and long duration, was observed as 
early as 1945. But the first paper on this blood pressure lowering agent was published 
five years later (Gross et al., 1950). One of the reasons for the delay was the 
unpleasant and acute side effects such as headache, nausea, vomiting, flushing, 
tachycardia and angina. However, in combination with other drugs, hydralazine is very 
useful for treating chronically hypertensive patients. The role of hydralazine in 
antihypertensive therapy has expanded, since it was demonstrated that the drug is 
particularly effective when combined with propranolol or other B adrenergic antagonists 
(Hansson et al., 1971; Zacest et al., 1972; Gotlieb et al., 1972; Koch-Weser 1974; 
Person, 1975). 
The characteristic action of hydralazine is the lowering of blood pressure, which 
in all species studied, including man is very similar. The onset of action is gradual, the 
maximum response is reached after 10 to 20 min, the degree of blood pressure 
reduction is limited and the duration of action is long (Gross et al., 195(5) ^ 
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In anesthetized and cx^nscious dogs a long lasting reduction in blood pressure 
was observed (Graver et al., 1951) but this acute hypotensive effect was less 
pronounced in rats (Bein and Brunner, 1965). In the spinal cat, in which the basal blood 
pressure is reduced to about 50-60 mm Hg, hydralazine did not induce further fall 
(Gross et al., 195q) 
In acute studies in man, together with the fall in blood pressure an increase in 
pulse pressure was observed and circulation time was shortened (Schmid and Kellner, 
19 3). Blood flow in the more dilated circulatory beds generally increased unless the 
fall in arterial pressure was very marked. Provost et al. (1981) observed that the 
hypotension induced by dihydralazine in normotensive and renal hypertensive rats was 
caused by decreasing peripheral resistance. Hydralazine caused a rapid fall in blood 
pressure and peripheral resistance in unrestrained spontaneous hypertensive rats lasting 
upto 24 hours. Immediately after injections of hydralazine the cardiac output and heart 
rate increased significantly (Struyker-Boudier et al., 1983). The reduction in peripheral 
vascular resistance is the result of a general vasodilation of the precapillary resistance 
vessels (Mellander and Johnson, 1968). Hydralazine affected postcapillary capacitance 
vessels much less than precapillary resistance vessels (Ablad, 1963). It has no 
appreciable effects on nonvascular smooth muscle. 
Although on the basis of the initial pharmacological studies on hydralazine it was 
supposed that the drug acted directly on the arteriolar smooth muscle, some data were 
available which suggested that there was a central site of action (Gross et al., 1950; 
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Graver et al., 1951; Baun et al., 1972; Fries et al., 1973; Daird et al., 
1975; Koch Weser, 1974. 1976). When the isolated brain of cat was perfused in situ, 
hydralazine, added to the perfusion fluid, produced a fall in blood pressure and 
tone of 
tachycardia together with a decrease in/tiind limb vasculature (Ingenito et al, 1969). 
However, other investigators reported contradictory results when hydralazine was 
injected into the cistqrna magna or the third ventricle of cats. Only a slight fall in the 
blood pressure was observed accompanied by a reduced pressor response to 
intravenously administered noradrenaline (Schmitt and Giguel, 1956). In cats only an 
enhanced chemoreceptor activity was observed after intracarotid injection, but there was 
no increase in the splanchnic activity. It was obvious that hydralazine behaved like a 
slow acting peripheral vasodilator (Dontas, 1957). From extensive studies of Ablad et 
al. (1963) it was evident that hydralazine exerts its hypotensive effect by means of a 
direct action on the vascular smooth muscle and has no influence on centers regulating 
blood pressure. Furthermore, injections of hydralazine into the vertebral artery of cat 
caused a hypotensive response similar to intravenous injection (Van Zweiten, 1968). In 
case of a central mechanism of action, the intravertebral injection should induce a more 
pronounced hypotensive reaction than the intravenous injections. 
The site of action of hydralazine appears to be primarily peripheral since it 
interferes with the hypertensive effect of several peripherally acting pressor substances 
including serotonin, epinephrine, norepinephrine and pitressin. Bein (1953) has shown 
that hydrazinophthalazine antagonizes the constrictor effect of ergotamine and 
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ephedrine after transection of the spinal cord, providing further evidence that 
hydralazine acts at the blood vessels. Bolt and Saxena (1984) observed that with higher 
doses of hydralazine the synergistic effect on blood pressure response disappeared 
due to an increase in cardiac output. Despite effective B adrenoceptor blockade the 
antihypertensive drugs acted synergistically only when low doses of hydralazine were 
used. 
Hydralazine tends to cause sodium and water retention, expansion of plasma and 
extracellular fluid volume, weight gain and edema formation (Koch Weser, 1974). These 
disturbances in electrolyte and fluid balance do not reflect decrease in renal blood flow 
or glomerular filtration rate, both of which are generally either increased or unchanged 
during hydralazine therapy (Judson et al, 1956). They are consequences of the 
reduction in arterial pressure and may be mediated both by the renin-angiotensin-
aldosterone system and by a direct renal mechanism. If expansion of plasma and 
extracellular fluid volume is avoided, tolerance to the antihypertensive action of 
hydralazine does not develop (Finnerty,1971). Treatment with hydralazine causes both 
right ventricular (RV) and left ventricular (LV) hypertrophy and accentric LV hypertrophy. 
Intravascular volume expansion associated with redistribution of blood volume to the 
central compartment, may play a major role in these cardiac effects. Increased renin 
release but not a generalized increase in sympathetic tone may play a role in the 
development of tolerance to the antihypertensive effect (Tsopris and Leeman, 1986). The 
reduction of arterial pressure in hypertensive patients during hydralazine therapy is 
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accompanied by an increase in peripheral plasma rer;iin activity (Ueda et al., 1968, 
1970). In conscious rabbits, the release of catecholamines and renin associated with 
hydralazine induced hypotension could be blocked by the prostaglandin synthetase 
inhibitor, indomethacin, the hypotensive response was also enhanced (Graham et al., 
1979). The release of renin by hydralazine in dogs could be antagonized by 
prostaglandin synthetase inhibitor only under conditions of preexisting elevated plasma 
renin levels, after surgical stress (Wang and Epokes, 1979). In contrast, the hypotension 
produced by hydralazine in conscious foxhounds was blocked by indomethacin, 
suggesting that the hypotensive responses are in some way mediated by 
prostaglandins (Brunner et al., 1965; Slack et al., 1978). Renal vasodilation produced 
by hydralazine may be mediated by prostaglandins since indomethacin also abolishes 
this effect (Spokes and Wang, 1976). These experiments suggest the involvement of 
prostaglandin in the action of hydralazine. A similar suggestion has been made by 
Chelly et al. (1986). Shepard et al. (1981) have stated that determining the acetylator 
index before giving hydralazine to the hypertensive patient is useful as the plasma 
hydralazine levels depend on the acetylator index. Hydralazine caused a slight increase 
in plasma renin activity and urinary excretion of noradrenaline in patients with essential 
hypertension (Velasco et al., 1985). 
Boenner et al. (1982) have suggested that the increased formation of kinins 
within the kidney could be involved in the vasodilator and blood pressure lowering 
effects of dihydralazine. 
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* Several cellular mechanism for the relaxatibn of vascular smooth muscle 
have been sugested. They are: chelation of certain trace metals l ike copper 
ions (Perry , 1953); inhibition of dopamine beta-hydroxylase (Lin et al . ,1974); 
interference with the entry of calcium from the extracellular store and the 
interference with calcium release from intracellular stores (McLean et a l . , 
1978); and activation of beta adrenoceptors in myocardium resulting in elevation 
of cyclic AMP. This could explain the increase in myocardial contracti l i ty. 
Although i t i s unlikely that the antihypertensive effects are due to catecholamine 
depletion, since repeated hydralazine treatment produces only transient change 
in catecholamine content of the vasculature (Gross, 1977). Some authors have 
suggested that increase in cyclic nucleotide concentration often found associated 
with relaxant effect on smooth muscle (Schultz et a l . , 1977) may not have 
a direct causal relationship with vascular relaxation (Diamond and Janis, 1978). 
It was considered that the excitatory effects of hydralazine at toxic doses 
might be closely associated with the changes in central GABAergic system (Satoh 
et a l . , 1981; Hara et a l . , 1983). Hara et a l . (1987) suggested that hydralazine 
might antagonize the pentylenetetrazol seizures at least part ly by modulating 
the activation of the central serotonergic system. 
RESERPINE 
The first reports on the antihypertensive propert ies of Rauwolfia 
serpentina and i ts derivatives were published by Bhatia (1942), Gupta et 
a l . (1943), Vakil (1949), Roy (1950) and Wilkins (1953). It was, 
however, only in early 1950's that Rauwolfia serpentina 
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preparation like reserpine were Introduced for the treatment of mild hypertension. It was 
soon established that reserpine was useful in reducing aggression also. It was also 
noted that the blood pressure and pulse rate were lowered (Wine. 1954). By the end 
of 1960's, reserpine had almost passed out of psychiatric use-being replaced by more 
efficacious drugs (Luby, 1968). Apart from drowsiness and sedation, reserpine also 
caused mood changes, especially depression. Depression has been reported in upto 
25 percent of patients, treated with reserpine (Aldrlch and Anchor, 1973) and even 
suicidal tendencies have been documented (Lemiex et al, 1956), Nasal stuffiness, which 
reflects cholinergic stimulation by reserpine can also be troublesome. However, 
reserpine still has a place in antihypertensive therapy (Freis, 1971). 
Reserpine acts on the central nervous system and the peripheral sympathetic 
system depleting norepinephrine stores in the brain and peripheral adrenergic nerve 
endings. It does so by inhibiting the uptake of its precursor dopamine, into the storage 
vesicle which contains the enzyme dopamine S hydroxylase. This action of reserpine 
also leads to reduced quantities of newly formed dopamine, which is not taken up and 
stored, and is more rapidly metabolized, primarily by monoamine oxidase (Ruttedge and 
Weiner, 1967). Thus reserpine is different from the classical centrally acting agents, as 
it appears to directly inhibit adrenergic mechanisms rather than work through the 
agonist actions postulated for the other agents. Nevertheless, the end results appear 
to be similar, that is, sympathetic outflow is decreased and vagal tone is increased. 
This latter effect may explain the decrease in heart rate seen with reserpine treatment 
24 
(Cohen et al,. 1968). 
Treatment of animals with reserpine resulted in depletion of catecholamines from 
the sympathetic ganglia, blood vessels, spleen, iris and other tissues with adrenergic 
innervation (Bertler et al., 1956, Paasonen and Krayer, 1958; Muschol, 1959; Sjostrand, 
1962; Berkowits et al., 1971). It also depletes the brain of Its content of noradrenaline 
(Holzbaner and Vogt, 1956) and serotonin (Karki and Paasonen, 1959). The depletion 
of these two amines in rabbit brain occurs in parallel time courses (Brodie et al., 
1957,). The depletion of dopamine in rabbit and sheep brain by reserpine takes place 
more rapidly than noradrenaline (Bertler et al., 1956). In pigeons reserpine causes 
depletion of serotonin in brain more rapidly than dopamine and noradrenaline (Jurio 
and Vogt, 1967). Not only are these interspecies differences but there are differences 
within a species also. Thus reserpine causes a more pronounced depletion of brain 
catecholamines in infant than in adult rats (Kulkarni and Sheidman, 1966). Dopamine 
synthesis in rat striatum is increased 3 to 4 times by in vivo treatment with reserpine 
whereas it doubles in the striatal synaptosomes (Vissari, 1982). 
Apart from the depleting effect of reserpine on adrenergic, dopaminergic and 
serotonergic neurons from their transmitters (Shore, 1972), It may also reduce brain 
acetylcholine storage capacity (Finberg, 1979). Treatment with reserpine results in an 
increase in the acetylcholine content of the brain of dog (Melhotra and Mehta, 1966), 
rat , Malptca et al., 1970) and cat (Malhotra and Prasad. 
1968). The effects of reserpine appear to be localized to certain regions, since in the 
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dog there is an increase in the acetylcholine content of the hypothalamus, but 
reserplne induced 
decrease in the hippocampus (Malhotra and Punlik, 1959). These/changes in 
cholinergic systems may be related to the changes in electrical activity of the 
hippocampus (Killam and Wllam, 1967). A cholinergic component 
has been reported in the response of the nictitating membrane of reserpinized cat 
(Martin and Cervoni, 1962). It is suggested that there are cholinergic fibers running with 
the adrenergic fibers in the sympathetic nerve trunk or a cholinergic mechanism is 
present in the adrenergic nerves (Burn and Rand, 1965). 
The administration of reserpine results in reduction of response of effector organs 
to stimulation of postganglionic adrenergic nerves, even though the effector organ 
remains responsive to injected noradrenaline (Gaffney et al.,1963). The loss of peripheral 
adrenergic transmission has a latency and occurs sometime after the appearance of 
the usual signs of the reserpine syndrome such as sedation, bradycardia, decrease in 
blood pressure and relaxation of the nictitating membrane. The loss of adrenergic 
transmission after reserpine treatment is not complete. Thus adrenergic nerve 
stimulation still produces positive inotropic response in guinea pig atria (Barnett and 
Benforado, 1966) and chicken heart (Bolton, 1967) but the response is abolished in 
rabbit (Hukovic, 1959). 
Although reserpine can deplete tissues of their catecholamine contents, some 
signs of increased sympathetic activity in response to release of catecholamines are 
also found. Reserpine gradually lowers blood pressure without causing an initial pressor 
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response in animals and man (McQueen et al., 1955; Bein, 1956). Reserpine induced 
depletion of catecholamines is accompanied by the release of inactive deaminated 
metabolites. This results in a decrease of active catecholamines at the site of action 
(Kopin and Gordon., 1962, 1963). A primary hypertensive response to reserpine is 
observed In spinal animals (Schmitt and Schmitt.. 1960) and in animals pretreated with 
ganglion blocking drugs (Bech et al., 1957). Both these procedures result in 
considerable enhancement of pressor response to adrenaline and noradrenaline. The 
hypotensive action of reserpine is greater In hypertensive patients than in normotensive 
ones, although the incidence of side effects do not differ in the two groups (McQueen 
et al., 1955). Similar observations have been made in rats (Fliickinger., 1969). 
Reserpine treated rats, subjected to procedures for producing renal hypertension 
failed to become hypertensive. The isolated perfused hind quarters of these rats exhibit 
a lesser vasoconstrictor action of noradrenaline than do those of untreated hypertensive 
rats (McQueen., 1961). In spontaneously hypertensive rats, reserpine has a more 
pronounced antihypertensive activity than in renal hypertensive rats (Ebinhera and 
Martz, 1970). 
The antihypertensive action of reserpine is often attributed to the loss of 
vasomotor and cardiac sympathetic tone consequent to the depletion of noradrenaline 
from the peripheral adrenergic nerves subserving cardiovascular control (Green,.1962). 
The depletion of noradrenaline from cardiovascular control centers in the hypothalamus, 
medulla and from neurons in the lateral horns of the spinal cord which make synaptic 
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connections with the thoracolumbar sympathetic preganglionic neurons, could also be 
responsible for the fall In blood pressure. 
Reserpine treatment increases both CNS a^  and 03 adrenoceptors (U'Prichard 
and Snyder, 1978), Bylund and Martinez (1980) have reported the induction of a^ 
binding sites in the rat salivary gland following reserpinization. Although reserpine 
depletes catecholamines, it also causes an upregulation of B adrenoceptors, which 
lithium is able to counteract (Treiser and Kellar, 1979) and it probably does this without 
reversing the reserpine induced catecholamine depletion. In contrast to the ability of 
lithium to antagonize dopamine antagonist induced supersensitivity, it enhances the 
behavioral supersensitivity following treatment with reserpine (Friedman et ai., 1979). 
According to Greenberg and Weiss (1979) repeated doses of reserpine to 3 month old 
rats produced dose related increase in [^H] dihyroalprenolol (DHA) binding in pineal 
gland, cerebral cortex and cerebellum. Reserpine increased DHA binding by increasing 
the density of B adrenoceptors. Reserpine induced supersensitivity to isoprenaline does 
not appear to involve a change in the affinity for B adrenoceptor or in receptor number 
as determined by [^H] DHA binding (Hawthorn and Broadley, 1982). Senas et al (1986) 
have suggested a different degree of sensitivity or response of the noradrenaline and 
adrenaline neurons following reserpine administration. 
Chronic treatment with reserpine, which depletes 5-HT stores or p-
chlorophenylalanine, 5HT synthesis inhibitor, elicited 20-30 % increase in [^H] 5-HT 
binding in numerous brain regions (Bennett and Snyder., 1976). Chronic reserpine 
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treatment is reported (Sharma et al., 1979) not to influence ['H] QNB binding sites in 
cortex and hippocampus. 
The evidence against the central site of action of 'antihypertensive drug# has 
been provided by several authors. Thus after treatment with reserpine, no diminution 
in electrical discharge In the preganglionic sympathetic nerves was observed which is 
expected following depression of sympathetic centers (Kobinger & Pichler,.1976). 
It is apparent from the available literature that even though a lot of work has 
been done on the physiological aspect of neurotransmitters but not much has been 
done to study the influence of repeated administration of antihypertensive drugs on 
central neurotransmitter receptors. It is important to determine the status of central 
receptors in animals treated chronically with antihypertensive drugs. The effect of 
antihypertensive drugs on these receptors will ultimately define the role of these 
receptors in the antihypertensive action of these drugs and in hypertension. 
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METHODOLOGY AND TECHNIQUE 
Albino, male rats of the Charles Foster strain, bred in the animal house of the 
Central Drug Research Institute were used. Rats weighing 100-150 g were taken and 
kept in standard laboratory conditions of temperature (23 ± 1.5 °CL humidity (50 ± 
10%) and dark light (5.00-18.00 h) cycle. The animals were allowed to acclimatize for 
four days before starting the experiment. 
Antihypertensive drugs were administered orally to rats for two months. The 
doses of these drugs were selected on the basis of several reports, and preliminary 
work done In our laboratory, indicating the best dose which could be used chronically 
and effectively. Clonidine (0.1 mg/kg) dissolved in water, centhaquin (0.1 mg/kg) 
synthesized in the Central Drug Research Institute was dissolved in 10 % ethanol, 
dihydralazine (Nepresol) (0.25 mg/kg) made by Ciba Geigy of India Ltd., was dissolved 
In water, reserpine (Serpasil) (1.25 mg/kg) made by Ciba Geigy of India Limited was 
also dissolved in water. These drugs were prepared fresh everyday just before the 
administration. 
1. RECEPTOR BINDING STUDIES: 
It is necessary, to differentiate between the two types of binding, one, which is 
specific to the type of receptor under investigation and the other, nonspecific binding 
to tissue biopolymers. The number of specific receptor sites are limited whereas the 
nonspecific sites are unlimited. The binding experiment was, therefore repeated in the 
presence of excess amount of non-radiolabelled ligand. Under these conditions it is 
likely that the radio labelled ligand would have minimal binding to the specific sites while 
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non-specific binding remained unaffected. The difference in tlie binding values for these 
two experiments gives the amount of specific binding. Repeating the two 
experiments for a range of labelled ligand concentrations helps in plotting down the 
results. This clearly shows that the amount of specifically bound ligand reaches a 
maximum despite the addition of increasing amounts of ligand. This situation would be 
expected if the number of specific receptors are limited. Such curves are capable of the 
mathematical analysis common to similar biochemical studies from which dissociation 
constants and the number of receptor sites are determined. 
1.1 Preparation of membranes: 
At the end of the two months of chronic drug treatment the animals were 
sacrificed and decapitated. Thereafter, specific areas of the brain like caudate, cortex, 
hypothalamus and medulla were dissected out in cold. Each brain area was weighed 
and then homogenized in 30 volumes of ice cold 50 mM Tris Hcl buffer (PH 7.4 at 20° 
c) containing 0.1% ascorbic acid, 120 nm pargyline, 5 nM potassium chloride and 
neuronal membranes were prepared. 
All the experiments were repeated thrice and the data was analyzed using least 
square regression analysis and analysis of variance. 
1.2 Binding of ^IH-dihydroergocryptine to a-adrenergic receptors 
The freshly dissected brain regions were homogenized in 30 volumes of 50 mM 
Tris-HCI buffer (pH 7.7 at 25 °C) using a motor driven teflon-glass tissue homogenizer. 
The tissue homogenate was centrifuged twice at 49,000 x g for 15 min in a refrigerated 
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Sorvall centrifuge after resuspending in fresh Tris buffer. The final pellet was 
suspended in 50 mM Tris buffer (pH 7.4 at 25 °C) consisting of 0.1% ascorbic acid, 120 
mM NaCI, 5 mM KCI, 2 mM CaClg and 10 nM pargyline to give a concentration of 10 
mg wet tissue per ml of incubation buffer. The standard assay mixture contained 0J2 ml 
of the homogenate, containing approximately 200 ILQ of tissue, 0.1 ml of ^H-
dihydroergocryptine, 0.1 ml of competing agent (phentolamine) and buffer to make up 
the total volume of 1 ml. Incubation was carried out in triplicate in a shaking water 
bath maintained at 37 °C for 10 min. At the end of the 10 min period, the contents of 
the incubation tubes were rapidly filtered under partial vacuum using Millipore manifold 
filtration unit and Whatman GF/C filters. It was followed by two 5 ml. washes of ice 
cold 50 mM Tris buffer (pH 7.4). The filters were transferred to liquid scintillation vials 
containing 10 ml of cocktail (composition : 2,5 diphenylonazole 4.9 M; 1,4-bis (5-pheny 
lanzolyl) benzene 200 ng, naphthalein 60 g; ethylene glycol 20 ml; methanol 100 ml; 
dioxane up to 1 litre). After an overnight equilibration period, the radioactivity was 
determined in a Packard Tricarb liquid scintillation spectrometer. The specific binding 
of ^H-dihydroergocryptine was defined as the difference in binding observed in the 
absence and in the presence of 1 iM unlabeled phentolamine. The specific binding was 
expressed as pmoles of ^H-dihydroergocryptine bound per g tissue. The specific 
binding of the radioligand (8 to 10 concentrations) was determined. This was followed 
by the Scatchard analysis to determine the dissociation constant (K )^ and the receptor 
density (B^^^) values. Four to five determinations were made to compute the means 
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and their standard errors. The data were analyzed by the ANOVA. 
1.3 Binding of 'H-dihydroalprenolol to B-adrenergic receptors 
The freshly dissected brain regions were homogenized and membranes prepared 
as described earlier. The final pellet was suspended in 50 mM Tris buffer to give a 
concentration of 10 mg wet tissue per ml of incubation buffer. The standard assay 
mixture contained 0.2 ml of the homogenate, containing approximately 200 nQ of tissue, 
0.1 ml of ^H-dihydroalprenolol, 0.1 ml of competing agent (propranolol) and buffer to 
make up the total volume of 1 ml. Incubaticns were carried out in triplicate in a shaking 
water bath mafntained at 37 °C for 10 min. The samples were filtered and the 
radioactivity was determined in a Packard Tricarb liquid scintillation spectrometer as 
described in section 1.2. The specific binding of ^H-dihydroalprenoiol was defined as 
the difference in binding observed in the absence and in the presence of 1 iM 
unlabeled propranolol. The specific binding was expressed as pmoles of ^H-
dihydroalprenolol bound per g tissue. The specific binding of the radioligand (8 to 10 
concentrations) was determined. This was followed by the- Scatchard analysis to 
determine the dissociation constant (K^ ,) and the receptor density (B^^ x) values. Four 
to five determinations were made to compute the means and their standard errors. The 
data were analyzed by the ANOVA. 
1.4 Binding of ^H-quinuclydinyl benzylate to cholinergic (muscarinic) receptors 
The membranes from freshly dissected brain regions were prepared as described 
in section 1.2. The standard assay mixture contaired 0.2 ml of the homogenate, 
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containing approximately 200 MQ of tissue, 0.1 ml of 'H-quinuclydinyl benzylate, 0.1 ml 
of competing agent (atropine) and buffer to make up the total volume of 1 ml. 
Incubation was carried out In triplicate in a shaking water bath maintained at 37 °C for 
10 min. At the end of the 10 min period, the contents of the incubation tubes were 
rapidly filtered and the radioactivity was determined in a Packard Tricarb liquid 
scintillation spectrometer. The specific binding of ^H-quinuclydinyl benzylate was 
defined as the difference in binding observed in the absence and in the presence of 
1 iiM unlabeled atropine. The specific binding were expressed as pmoles of ^H-
quinuclydinyl benzylate bound per g tissue. The specific binding of the radioligand (8 
to 10 concentrations) was determined. This was followed by the Scatchard analysis to 
determine the dissociation constant (K^) and the receptor density {B^^x) values. Four 
to five determinations were made to compute the means and their standard errors. The 
data were analyzed by the ANOVA. 
1.5 Binding of ^H-spiroperldol to dopamine receptors 
The membranes from freshly dissected brain regions were prepared as described 
earlier in section 1.2. The standard assay mixture contained 02. ml of the homogenate, 
containing approximately 200 HQ of tissue, 0.1 ml of ^H-spiroperidol, 0.1 ml of 
competing agent (haloperidol) and buffer to make up the total volume of 1 ml. 
Incubation and filteration were carried out as described before. The filters were 
transferred to liquid scintillation vials and the radioactivity was determined in a Packard 
Tricarb liquid scintillation spectrometer. The specific binding of ^H-spiroperidol was 
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defined as the difference in binding observed in the absence and in the presence of 
1 nM unlabeled haloperidol. TTie specific binding was expressed as pmoles of ^H-
spiroperidol bound per g tissue. The specific binding of the radioligand (8 to 10 
concentrations) was determined. This was followed by the Scatchard analysis to 
determine the dissociation constant (K )^ and the receptor density ( B „ ^ values. Four 
to five determinations were made to compute the means and their standard errors. The 
data were analyzed by the ANOVA. 
1.6 Binding of 'H-S-HT to 5HT, receptors 
The binding assays for 'H-5-HT was carried out as described before except that 
8-10 concentrations (0.25 to 20 nM) of the ligand were used. The tissue in each tube 
was about 300 ^g. The incubation was carried out for 15 min in a shaking water bath 
maintained at 37 **C. At the end of the incubation period, the contents of the incubation 
tubes were filtered rapidly under partial vacuum using Whatman GF/C filter discs on a 
Mllllpore manifold filtration unit. The washing and counting of radioactivity was done 
as described before for other receptor studies. The specific binding was defined as 
the difference in binding of ^H-5-HT in the absence and presence of 10 KM 5-HT. The 
B a^x ="^ d Kj values were determined by Scatchard analysis. 
1.7 Binding of 'H-splroperldol to S-HTj, receptors 
The freshly dissected brain regions were homogenized and neuronal membranes 
prepared as described in section 1.2. The standard assay mixture containBdO.2 ml of 
the homogenate. containing approximately 200 ng of tissue, 0.1 ml of ^H-spiroperidol, 
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0.1 ml of competing agent (ketanserin) and buffer to make up the total volume of 1 ml. 
Incubation and filteration was done and radioactivity determined as described earlier, 
•followed by two 5 ml. washes of ice cold 50 mM Tris buffer (pH 7.4). The specific 
binding of 'H-spiroperidol was defined as the difference in binding observed in the 
absence and in the presence of 1 nM unlabeled ketanserin. The specific binding was 
Table 1 : Summary of the various ligands used for radioreceptor binding to different 
neurotransmitter receptors 
Receptor 
a-adrenergic 
B-adrenergic 
Muscarinic 
Dopamine 
5-hydroxytry-
ptamine 
(5HT,) 
5-hydroxytr-
yptamineg 
(5HT2) 
Hot ligand 
^H-Dihydroergocryptine 
0.25-12 nM (Amersham) 
^H-Dihydroalprenolol 
0.12-4 nM (Amersham) 
^H-Quinuclidinyl 
benzylate 0.1-2 nM (NEN) 
^H-Spiperone 
0.1-5 nM (NEN) 
^H-5-hydroxytryptamine 
0.25-15 nM (NEN) 
'H-Spiperone 
0.15-10 nM (NEN) 
Cold ligand 
Phentolamine 
(1MM) 
Propranolol 
(1 MM) 
Atropine 
(1 M 
Haloperidol 
(1 MM) 
5-hydroxytry-
ptamine(5-HT) 
(1 MM) 
Ketanserin 
(1 MM) 
expressed as pmoles of ^H-spiroperidol bound per g tissue. The specific binding of the 
radioligand (8 to 10 concentrations) was determined. This was followed by the 
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Scatchard analysis to determine the dissociation constant (K )^ and the receptor density 
(Bnwx) values. Four to five determinations were made to compute the means and their 
standard errors. The data were analyzed by the ANOVA. 
2. EFFECTS OF CENTHAQUIN ON BLOOD PRESSURE AND HEART RATE IN 
NORMAL AND CERVICAL SECTIONED RATS 
Albino rats were anaesthetized with urethane (1.2 g/kg, ip). The femoral artery 
was cannulated and connected to a Statham P23DC pressure transducer and a Grass 
low level 7PIDC preamplifier on a Grass Model 7 polygraph for recording the blood 
pressure. While the heart rate was recorded on another channel of the polygraph 
through a 7P44 tachograph preamplifier. The trachea was cannulated and the animal 
was maintained on artificial respiration. The skin was cut from the occipital protuberance 
to the lower cervical region. Then the atlanto-occipital membrane was exposed and the 
dorsal part of the cervical vertebra was nibbled, exposing the spinal cord. Spinal cord 
sectioning was performed and a part of the cervical (C2 to C4) region of spinal cord 
was removed so that there was absolutely no connection with the brain. 
In some of the rats intrathecal cannulation was performed to determine the effect 
of intrathecal administration of centhaquin on blood pressure and heart rate. A PE10 
tubing was guided into the spinal canal through a small opening made in the atlanto 
occipital membrane. The cannula was pushed gently till 8 cm mark was reached. The 
location of cannula was confirmed after the experiment by injecting dye and dissecting 
open the spinal canal and locating the dye. Volume of injection was 2 n\ for each drug 
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and normal saline was without effect on blood pressure and heart rate. 
3. MICROINJECTION STUDIES OF CENTHAQUIN IN CATS 
Cats (2.5-4.5 kg) of either sex were used as experimental animal for the study. 
They were anaesthetized with alpha chloralose (80 mg/kg, Iv). Blood pressure was 
recorded from the right femoral artery through a Statham P23DC pressure transducer 
and a Grass low level ZPIDC preamplifier on a Grass Model 7 polygraph. Heart rate 
was recorded on another channel of the polygraph through a 7P44 tachograph 
preamplifier. Trachea was cannulated and the animal maintained on artificial respiration. 
The head of the animal was fixed in David Kopf Stereotaxic frame, and the stereotaxic 
technique was used to hold the animal in the frame through out the experiment .two 
burr holes were made on the skull to mark the position of the nucleus tractus solitarius 
(NTS) at parameters of p=10, L=2-3, V=-6 (Snider and Neimer, 1961). A cannula was 
placed in the NTS using the above parameters and drugs like centhaquin, clonidine, 
phentolamine, yohimbine and prazosin were injected wiftithe help of a microsyringe. A 
maximum volume of 10 MI was injected in the NTS and saline (10 MI) did not produce 
any effect on blood pressure and heart rate. 
3.1 Confirmation of Cannula Location: To confirm the location of the cannula, 10 
ui of Evans blue or methylene blue was injected into the nucleus tractus solitarius 
(NTS) at the end of the experiment. The animals were sacrificed by an overdose of 
magnesium sulfate and the brain was removed from the skull and fixed in 10% formalin 
for 48 h. The brain was removed and its sections were examined. The location of dye 
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in the region of NTS confirmed the site of injection. 
4. STUDIES ON THERMOREGULATION AND BLOOD PRESSURE 
Groups of six pretreated rats were taken and allowed to acclimatize at the 
desired ambient temperature for two hours before starting the experiment. The 
experimental animals were administered drug into the lateral cerebral ventricle (icv) 
through a chronically, implanted cannula. 
4.1 Placement of the Cannula In Lateral Cerebral Ventricle: Rats were 
anaesthetized with pentobarbitone sodium (30 mg/kg, i.p). After shaving and cleaning 
the skull, the head was fixed in a rat stereotaxic frame (David Kopf). A 2 cm long 
midline incision was made to expose the skull, and a I mm hole was drilled with a 
dental burr, 2.5 mm lateral and 3.5 mm anterior to the interaural plane. A 14 mm long 
20 gauge stainless steel tube with a small stainless steel plate fixed 2 mm from its lower 
end served as the cannula. The cannula was held in the electrode holder of the 
stereotaxic instrument and was lowered vertically into the hole after puncturing the dura 
with a cutting needle. The steel plate was fixed to the skull with dental cement, the 
wound was sutured in layers and sealed with cotton wool soaked in tincture benzoin. 
A stainless steel wire of appropriate length and thickness was used as stilette. Usually, 
the recovery was uneventful, and the wound healed within a week. After that, the 
animals exhibited normal behavior, without any neurological deficit indicating that they 
were fit for experimentation. The cannulated rats were used several times, with 
reproducible responses. All surgery was performed aseptically. 
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4.2 Preparation of Drugs: ITie drugs used were noradrenaline, dopamine, 5-HT 
and acetylcholine. The drug solutions were freshly prepared in pyrogen free normal 
saline. All the glassware was sterilized at 180 "C for 5 hours in a dry oven, syringes 
and needles were autoclaved and all solutions were filtered immediately before use, in 
a Maxiflow microfilter of 0.45 Mm pore size to ensure that they were free from pyrogen 
producing bacteria. 
4.3 Drug Administration: The amount of drug to be injected was dissolved in a 
constant volume of 10 ^1. and injected into the lateral ventricle (icv) through the 
implanted cannula i^itti the help of a Hamilton microsyringe of 50 MI, fitted with a number 
27 hypodermic needle. A rubber disk fixed 12 mm from the tip of the needle served as 
a stopper during drug administration. The stilette was replaced immediately after 
injection of the drug. 
4.4 y Confirmation of Cannula Location: To confirm the location of the cannula, 10 
ii\, of 1% Evans blue or methylene blue was injected into the lateral cerebral ventricle 
at the end of the experiment. The animals were sacrificed by an overdose of 
pentobarlpitone sodium, and the skull with the brain was fixed in 10% formalin for 48 
h. The brain was then removed and its sections were examined. It showed that the dye 
was uniformly distributed throughout the cerebral ventricles. 
4.5 Temperature Measurements: The core temperature of the albino rats was 
measured with a thermistor probe inserted 2 cm into the rectum and connected to a 
programmed Apple computev-. The temperature was recorded before the drug 
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administration and immediately after it at regular intervals of 10 minutes for 5 hours. 
The temperature duration from basal value for each animal and the mean 
duration for the group along with standard error (SE) were worked out. The time course 
of temperature change was plotted for each animal and the area under the curve 
measured with a planimeter. 
4.6 Blood Pressure Measurement 
The blood pressure of conscious albino rats was recorded by the HTC in 6 
instrument. It serves to amplify photoelectrically detected tail pulses of mod B 60 type 
sensing cuffs. The available outputs also serve in conjunction with a dual channel 
recorded (IITC Model 45) to give permanent paper recordings to show the presence 
of tail pulses on one channel and the matching cuff pressure on the other channel. The 
animals were put into the rat holders which were connected to the manual scanner of 
the system. The tail pulses with the cuff pressure was recorded before the drug 
administration and after for 4 hours. 
The IITC method measures the systolic as well as the mean blood pressure of 
rodents. The first onset of pulses is taken as the systolic point and the first maximum 
amplitude is taken as the Mean BP point. The diastolic BP is calculated by the formula 
Diastolic BP = 3(Systolic BP - Mean BP) * 2. The blood pressure before administration 
of the drug was compared to the change in blood pressure after the drug injection. 
4.7 Statistics: The significance of the difference between the two groups was 
assessed by employing the students 't' test. 
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RESULTS 
1. STUDIES ON RADIORECEPTOR BINDING: 
1.1 EFFECT OF CHRONIC ADMINISTRATION OF ANTIHYPERTENSIVE DRUGS 
ON o ADRENOCEPTORS: 
The population (B^ j^^ ) of the adrenoceptors in norma! rat brain Is fairly constant 
in all the four areas. In cortex the B „ ^ value was 30.21 ± 1.38 pmol/g tissue. While the 
Kj value was 0.81 ± 0.12 nM. In caudate the density was (B„„)41.49 ± 2.19 pmol/g 
tissue while the affinity was (K^JI .24 ± 0.23 nM . Hypothalamus showed the B^^ x value 
of 32.89 ± 2.19 pmol/g tissue, and the K^ , value was 0.68 ± 0.11 nM. In medulla the 
B a^x value was 31.09 ± 1.30 pmol/g tissue, while the K^  value was 0.66 ± 0.20 nM. 
In cortex the population (B^,^ 29.01 ± 1.79 pmol/g tissue) and affinity (K^ 0.77 
± 0.16 nM) of ^H-dihydroergocryptine binding, remained unchanged in the centhaquin 
treated rats. In the clonidine treated rats also the population (B^., 30.53 ± 1.54 pmol/g 
tissue) and affinity (K ,^ 0.83 ±0.14 nM) remained unchanged. In hydralazine treated rats 
the population {B„^^ 23.18 ±1.11 pmol/g tissue) decreased (p < 0.05), but the affinity 
(Kj, 0.76 ±0.12 nM) remained unchanged. In reserpine treated rats the density (B^g^ 
21.94 ± 1.20 pmol/g tissue) decreased (p < 0.05) but no change occurred in the 
affinity (K^ 0.80 ± 0.11 nM) of ^H-dihydroergocryptine binding (Table 1; Figures 1 and 
2). 
In the caudate, treatment by centhaquin did not alter either the density (B^gx 
44.80 ± 2.31 pmol/g tissue) or the affinity (K^ 1.41 ± 0.19 nM) of ^H-dihydroergocyptine 
binding. Treatment by clonidine did not affect the density {B^^ 45.24 ± 1.99 pmol/g 
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Table 1. Effect of repeated administration of centhaquin, cionidine, hydralazine and reserpine on ^ H-
dihydroergocryptine binding to a adrenergic receptors in rat cerebral cortex. 
Treatment ^H-Dihydroergocryptine binding 
Mean ± S.E.M., N=5 
Bn„„ (pmol/g tissue) K^  (nM) 
Vehicle 30.21 ± 1.38 0.81 ±0 .12 
Centhaquin 29.00 ± 1.79 0.77 ±0 .16 
Cionidine 30.53 ± 1.54 0.83 ± 0.14 
Hydralazine 23.18 ± 1.11* 0.76 ± 0.12 
Reserpine 21.94 ± 1.20* 0.80 ±0 .11 
*P < 0.05 as compared to vehicle treated control 
Table 2. Effect of repeated administration of centhaquin, cionidine, hydralazine and reserpine on ^H-
dihydroergocryptine binding to a adrenergic receptors in rat corpus striatum. 
Treatment ^H-Dihydroergocryptine binding 
Mean ± S.E.M., N=5 
^max (Pmol/g tissue) Kj (nM) 
Vehicle ,41.49 ±2 .19 1.24 ± 0.23 
Centhaquin 44.80 ± 2.31 1.41 ± 0.19 
Cionidine 45.24 ±1 .99 1.43 ± 0.14 
Hydralazine 30.72 ± 1.24* 1.03 ± 0.16 
Reserpine 28.17 ± 1.16* 1.07 ± 0.13 
*P < 0.05 as compared to vehicle treated control 
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tissue) or affinity (K^ 1.43 ± 0.14 nM) of these receptors. Treatment with reserpine 
decreased (p < 0.05) the population ( B „ „ 28.17 ± 1.16 pmol/g tissue) but the affinity 
(Kj 1.07 ± 0.13 nM) of 'H-dihydroergocryptine binding did not change. Similarly, 
treatment with hydralazine decreased (p < 0.05) the population ( B „ „ 30.72 ± 1.24 
pmol/g tissue) but the affinity (K^ 1.03 ± 0.16 nM) of 'H-dihydroergocryptine binding 
did not change (Tablfe 2; Figures 3 and 4). 
In hypothalamus, the density (B„^) increased (p < 0.05) by centhaquin treatment 
(50.12 ± 2.32 pmol/g tissue) while K^  (0.94 ± 0.20 nM) did not change. Clonidine 
treatment also increased the density (B „^ = 43.31 ± 1.92 pmol/g tissue) while the 
affinity (K^ = 0.87 ±0.16 nM) did not change. Hydralazine treatment decreased the 
density (B^a^ 23.67 ± 1.1 pmol/g tissue), while the affinity (K^ 0.65 ± 0.13 nM) was not 
altered. Reserpine treatment decreased (p < 0.05) the density {B^^ = 20.65 ± 1.16 
pmol/g tissue) while the Kg, (0.57 ± 0.09 nM) of ^H-dihydroergocryptine binding was 
unchanged (Table 3; Figures 5 and 6). 
In the medulla of centhaquin treated rats the density (B^.^ 57.79 ± 2.78 pmol/g 
tissue)increased (p < 0.05) and no change occurred in affinity (K^ 0.92 ±0.18 nM). In 
clonidine treated rats the density {B^^ 49.41 ± 2.29 pmol/g tissue) increased (p < 
0.05) while the affinity (K^ 0.87 ±0.14 nM) did not alter. In hydralazine treated rats the 
density {B^„ 23.49 ±1.12 pmol/g tissue) of these receptors decreased (p < 0.05), but 
no change occurred in the affinity (K^ 0.65 ±0 .16 nM). In reserpine treated rats the 
density {B^^^ 19.65 ±1.11 pmol/g tissue) decreased (p < 0.05) but no change was 
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Table 3. Effect of repeated administration of centhaquin, clonidine, hydralazine and reserpine on ^H-
dihydroergocryptine binding to a adrenergic receptors in rat hypothalamus. 
Treatment ^H-Dihydroergocryptine binding 
Mean ± S.E.M., N=5 
Bmax (pmol/g tissue) Kj(nM) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
32.89 ±2 .19 
50.12 ± 2.32* 
43.31 ± 1.92* 
23.67 ± 1.10* 
20.65 ± 1.16* 
0.68 ± 0.11 
0.94 ± 0.20 
0.87 ±0 .16 
0.65 ±0 .13 
0.57 ± 0.09 
'P < 0.05 as compared to vehicle treated control 
Table 4. Effect of repeated administration of centhaquin, clonidine, hydralazine and reserpine on -^ H-
dihydroergocryptine binding to a adrenergic receptors in rat brain medulla. 
Treatment H-Dihydroergocryptine binding 
Mean ± S.E.M., N=5 
Bmax (pmol/g tissue) Kd(nM) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
31.09 ± 1.30 
57.79 ± 2.78* 
49.41 ± 2.29* 
23.49 ± 1.12* 
19.65 ± 1.11* 
0.66 ± 0.20 
0.92 ±0 .18 
0.87 ±0 .16 
0.65 ±0 .16 
0.54 ± 0.11 
T < 0.05 as compared to vehicle treated control 
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observed in the affinity (K^ 0.54 ± 0.11 nM), of *H-dihydroergocryptine binding (Table 
4; Figures 7 and 8). 
1.2 EFFECT OF CHRONIC ADMINISTRATION OF ANTIHYPERTENSIVE DRUGS ON 
B-ADRENOCEPTORS: 
In normal rat brain the B-adrenoceptors have high affinity (K )^ binding sites. In 
cortex the B^^ value was 38.76 ± 2.57 pmol/g tissue and the K^  value was 0.80 ± 
0.05 nM. In caudate the density was (B„„ 35.77 ± 1.44 pmol/g tissue. While the affinity 
was (Kj 1.76 ± 0.07 nM). In hypothalamus the B „ „ value was 24.88 ± 2.11 pmol/g 
tissue, while the K^  value was 0.58 ± 0.04 nM. Medulla showed the B^^^ value of 31.77 
± 1.73 pmol/g tissue, and the K^  value of 0.68 ± 0.06 nM. 
In the cortex, centhaquin treatment did not affect the density (Bn,^ ^ 39.50 ± 1.88 
pmol/g tissue) and affinity (K^ 0.74 ± 0.04 nM) of ^H-dihydroalprenolol binding. 
Clonidine also did not affect either the density (B^.^ 38.37 ± 2.30 pmol/g tissue) or the 
affinity (K^ 0.72 ± 0.11 nM) of 3-adrenoceptors. Hydralazine treatment increased (p < 
0.05) both the density (B^,^ 52.41 ± 2.02 pmol/g tissue) and affinity (K^ 0.96 ± 0.04 
nM) of ^H-dlhydroalprenolol binding. While reserplne treatment increased only the 
density (B^3^ 47.96 ± 2.01 pmol/g tissue) but the affinity (K^ 0.68 ± 0.03 nM) of B-
adrenoceptors did not change (Table 5; Figures 9 and 10). 
In caudate, no change was observed in the density {B^^x 38.88 ± 1.86 pmol/g 
tissue) and affinity (K^ 1.54 ± 0.06 nM) by centhaquin treatment. Clonidine treatment 
also produced no change in the density (B^„ 35.21 ±1.11 pmol/g tissue) and affinity 
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Table 5. Effect of repeated administration of centhaquin, clonidine, hydralazine and reserpine on ^ H-
dihydroalprenolol binding to B adrenergic receptors in rat cerebral cortex. 
Treatment ^H-Dihydroalprenolol binding 
Mean ± S.E.M., N=5 
Bmax (pmol/g tissue) Ka(nM) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
38.76 ± 2.57 
39.50 ± 1.88 
38.37 ± 2.30 
52.41 ± 2.02* 
47.96 ± 2.01* 
0.80 ± 0.05 
0.74 ± 0.04 
0.72 ±0.11 
0.96 ± 0.04* 
0.68 ± 0.03 
*P < 0.05 as compared to vehicle treated control 
Table 6. Effect of repeated administration of centhaquin, clonidine, hydralazine and reserpine on "^ H-
dihydroaiprenoiol binding to B adrenergic receptors in rat corpus striatum. 
Treatment •'H-Dihydroalprenolol binding 
Mean ± S.E.M., N=5 
Bmax (pmol/g tissue) Kd(nM) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
35.77 ±1 .44 
38.88 ± 1.86 
35.21 ±1 .11 
46.11 ± 1.86* 
41.40 ± 1.06* 
1.76 ± 0.07 
1.54 ± 0.06 
1.89 ± 0.05 
1.47 ± 0.06 
1.58 ± 0.05 
*P < 0.05 as compared to vehicle treated control 
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Table 7. Effect of repeated administration of centhaquin, donidine, hydralazine and reserpine on ^H-
dihydroalprenolol binding to B adrenergic receptors in rat hypothalamus. 
Treatment ^H-Dihydroalprenolol binding 
Mean ± S.E.M., N=5 
Bin« (pmol/g tissue) Kj (nM) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
24.8 ±2.11 
25.33 ± 1.90 
25.74 ± 1.41 
32.00 ± 1.12* 
35.87 ±1.11* 
0.58 ± 0.04 
0.66 ± 0.05 
0.52 ± 0.05 
0.46 ± 0.07 
0.55 ± 0.06 
*P < 0.05 as compared to vehicle treated control 
Table 8. Effect of repeated administration of centhaquin, clonidine, hydralazine and reserpine on •'H-
dihydroalprenolol binding to B adrenergic receptors in rat brain medulla. 
Treatment ^H-Dihydroalprenolol binding 
Mean ± S.E.M., N=5 
Bmax (pmol/g tissue) Kd(nM) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
31.77 ± 1.73 
31.70 ± 2.04 
32.27 ± 2.29 
24.44 ± 1.66* 
21.59 ± 1.08* 
0.68 ± 0.06 
0.68 ± 0.08 
0.66 ± 0.05 
0.68 ± 0.04 
0.59 ± 0.08 
*P < 0.05 as compared to vehicle treated control 
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(Kj 1.89 ± 0.05 nM). In hydralazine treated rats the receptor density (B^.^ 46.11 ± 1.86 
pmol/g tissue) increased (p < 0.05) but the affinity (K^ 1.47 ± 0.06 nM) of 'H-
dihydroalprenolol binding remained unchanged. In reserpine treated rats the density 
(Bmax 41.40 ± 1.06 pmol/g tissue) Increased (p < 0.05) and the affinity (K^ 1.58 ± 0.05 
nM) remained unchanged (Table 6; Figures 11 and 12). 
In hypothalamus the population (B,^ 25.33 ± 1.90 pmol/g tissue) and affinity (K^ 
0.66 ± 0.05 nM) did not change by centhaquin treatment. With clonidine treatment also 
the population (B^^ 25.74 ± 1.41 pmol/g tissue) and affinity (K^ 0.52 ± 0.05 nM) 
remained unchanged. Hydralazine treatment increased (p < 0.05) the density {B^^x 
32.00 ± 1.12 pmol/g tissue) while the affinity was unchanged (K^ 0.46 ± 0.07 nM). 
Reserpine treatment increased (p < 0.05) the density (B^g^ 35.87 ±1.11 pmol/g tissue) 
but no change was seen in affinity (K^ 0.55 ± 0.06 nM) of 'H-dihydroalprenelol binding 
(Table 7; Figures 13 and 14). 
In medulla, centhaquin treatment did not change the density (B^.^ 31.70 ± 2.04 
pmol/g tissue) or the affinity (K,, 0.68 ± 0.08 nM) of the 'H-dihydroalprenolol binding. 
Clonidine treatment also did not change either the density (B^^^ 32.27 ± 2.29 pmol/g 
tissue) or affinity (K^ 0.66 ± 0.05 nM). By hydralazine treatment the density {B^^ 24.44 
± 1.66 pmol/g tissue) decreased (p < 0.05), no significant change was observed in the 
affinity (K^ 0.68 ± 0.04 nM). Reserpine treatment produced a decrease in the density 
(B a^x 21 -59 ± 1.08 pmol/g tissue) (p < 0.05) while no change occurred in the affinity 
(Kj 0.59 ± 0.08 nM) of B-adrenoceptors (Table 8; Figures 15 and 16). 
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1.3 EFFECT OF CHRONIC ADMINISTRATION OF ANTIHYPERTENSIVE DRUGS ON 
DOPAMINERGIC RECEPTORS: 
The normal rat brain dopaminergic sites, labelled by *H-spiroperidol in the 
caudate show high density ( B „ ^ 58.68 ± 2.09 pmol/g tissue) and high affinity (K ,^ 0.03 
± 0.01 nM) binding sites. In cortex the density was (B^^ 46.63 ± 1.70 pmol/g tissue 
whereas the K^  was .0.43 ± 0.09 nM. In caudate the B „ „ value was 58.68 ± 1.33 
pmol/g tissue, while the K^  value was 0.03 ± 0.01 nM. The hypothalamus showed B^ jg^  
value of 25.23 ± 0.92 pmol/g tissue and K^  value of 0.31 ± 0.04 nM. In medulla the 
Bmax was 44.49 ± 1.68 pmol/g tissue, while K^  was 0.39 ± 0.05 nM. 
In cortex, centhaquin treatment decreased (p < 0.05) the population (B^^x 34.86 
± 1.39 pmol/g tissue) and no change occurred in the affinity (K^ 0.35 ± 0.15 nM). 
Clonidine treatment increased (p < 0.05) the density {B^^ 54.84 ± 1.96 pmol/g tissue), 
while no change occurred in the affinity (K^ 0.48 ± 0.09 nM). Hydralazine treatment 
decreased (p < 0.05) the density (B^^ 31.49 ± 1.24 pmol/g tissue) without any change 
in the affinity (K,, 0.44 ± 0.06 nM). Reserpine treatment also decreased (p < 0.05) the 
density (B^^^ 37.37 ± 1.86 pmol/g tissue) with no change in the affinity (K^ 0.43 ± 0.08 
nM) (Table 9; Figures 17 and 18). 
In caudate, no change occurred in the density {B^^ 58.03 ± 1.33 pmol/g tissue) 
or affinity (K^ 0.03 ± 0.01 nM) of centhaquin treated rats. In the clonidine treated rats 
also there was no change in the density (B^„ 58.05 ± 1.26 pmol/g tissue) or affinity 
(Kj 0.03 ± 0.01 nM). In hydralazine treated rats there was no change in the density 
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Table 9. Effect of repeated administration of centhaquin, clonidine, hydralazine and reserpine on • 'H-
spiroperidol binding to dopaminergic receptors in rat cerebral cortex. 
Treatment 'H-Spiroperidol binding 
Mean ± S.E.M., N=:5 
B „ „ (pmol/g tissue) Ka(nM) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
46.63 ± 1.70 
34.86 ± 1.39* 
54.84 ± 1.96* 
31.49 ± 1.24* 
37.37 ± 1.86* 
0.43 ± 0.09 
0.35 ±0 .15 
0.48 ± 0.09 
0.44 ± 0.06 
0.43 ± 0.08 
"P < 0.05 as compared to vehicle treated control 
Table 10. Effect of repeated administration of centhaquin, clonidine, hydralazine and reserpine on ^H-
spiroperidol binding to dopaminergic receptors in rat corpus striatum. 
Treatment ^H-Spiroperidol binding 
Mean ± S.E.M., N=5 
Bmax (Pmol/g tissue) Kd(nM) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
58.68 ± 2.09 
58.03 ± 1.33 
58.05 ± 1.26 
59.26 ± 1.94 
56.42 ± 1.84 
0.03 ± 0.01 
0.03 ± 0.01 
0.03 ± 0.01 
0.03 ± 0.01 
0.04 ± 0.01 
*^P < 0.05 as compared to vehicle treated control 
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Table 11. Effect of repeated administration of centhaquin, clonidine, hydralazine and reserpine on ^l-l-
spiroperidol binding to dopaminergic receptors in rat hypotlialamus. 
Treatment ^IH-Spiroperidol binding 
Mean ± S.E.M., N=5 
Bm-x (pmoi/g tissue) Ktf(nM) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
25.23 ± 0.92 
24.74 ± 0.90 
26.66 ± 0.97 
19.01 ± 1.26* 
31.39 ± 1.01* 
0.31 ± 0.04 
0.30 ± 0.05 
0.32 ± 0.07 
0.31 ± 0.05 
0.29 ± 0.06 
'P < 0.05 as compared to vehicle treated control 
Table 12. Effect of repeated administration of centhaquin, clonidine, hydralazine and reserpine on "^ H-
spiroperidol binding to dopaminergic receptors in rat brain medulla. 
Treatment ^H-Spiroperidol binding 
Mean ± S.E.M., N=5 
Bmax (pmol/g tissue) Kd(nM) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
44.49 ± 1.68 
43.37 ± 1.63 
43.84 ± 1.49 
37.71 ± 1.16* 
37.13 ± 1.11* 
0.39 ± 0.05 
0.43 ± 0.08 
0.43 ± 0.07 
0.32 ± 0.07 
0.30 ± 0.05 
"P < 0.05 as compared to vehicle treated control 
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( B „ „ 59.26 ± 1.94 pmol/g tissue) or affinity (K^ 0.03'± 0.01 nM). And also in the 
reserpine treated rats no change was seen in either density (B „ ^ 56.42 ± 1.84 pmol/g 
tissue) or affinity (K^ 0.04 ± 0.01 nM) of the dopamine receptors (Table 10; Figures 19 
and 20). 
In hypothalamus no change was observed in the population (B^ „ 24.74 ± 0.90 
pmol/g tissue) and affinity (K^ 0.30 ± 0.05 nM) by centhaquin. Clonidine also produced 
no change in the density ( B „ „ 26.66 ± 0.97 pmol/g tissue) and affinity (K^ 0.32 ± 0.07 
nM), of these receptors. Hydralazine treatment produced a decrease (p < 0.05) in the 
density (B^,^ 19.01 ± 1.26 pmol/g tissue) while the affinity (K^ 0.31 ± 0.05 nM) of ^H-
spiperone binding remained unchanged. Reserpine treatment increased (p < 0.05) the 
density {B^^^ 31.39 ± 1.01 pmol/g tissue) while the affinity (K^ 0.29 ± 0.06 nM) of ^H-
spiperone binding remained unchanged (Table 11; Figures 21 and 22). 
In the medulla, the dopaminergic receptor population (B^^^ 43.37 ± 1.63 pmol/g 
tissue) and affinity (K^ 0.43 ± 0.08 nM) remained unchanged by centhaquin treatment. 
In the clonidine treated rats also the population ( B „ „ 43.84 ± 1.49 pmol/g tissue) and 
affinity (K^ 0.43 ± 0.07 nM) of ^H-spiperone binding remained unchanged. In the 
hydralazine treated rats the density (B^„ 37.71 ±1.16 pmol/g tissue) decreased (p < 
0.05) and the affinity (K^ 0.32 ± 0.07 nM) remained unchanged. In the reserpine treated 
rats the density (B^^x 37.13 ±1.11 pmol/g tissue) decreased (p < 0.05) and the affinity 
(Kj 0.30 ± 0.05 nM) of the 'H-spiperone binding remained unchanged (Table 12; 
Figures 23 and 24). 
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1.4 EFFECT OF CHRONIC ADMINISTRATION OF ANTIHYPERTENSIVE DRUGS 
ON CHOLINERGIC (MUSCARINIC)-RECEPTORS: 
In the normal rat brain the distribution of muscarinic receptor sites show that in 
cortex the Bn,„ value was 51.13 ± 1.92 pmol/g tissue and K^  value was 0.78 ± 0.09 
nM. Caudate shows the B „ „ of 63.10 ± 2.20 pmol/g tissue and K^  of 0.77 ± 0.11 nM. 
In hypothalamus the density was (B^g^ 36.53 ± 1.63 pmol/g tissue) and affinity was K^  
1.42 ± 0.09 nM). In medulla the density was ( B „ „ 39.93 ± 1.83 pmol/g tissue, and 
affinity was (K^ 0.73 ± 0.06 nM). These receptors have high affinity binding sites in 
various brain regions. 
In cortex, centhaquin treatment produced no change in the density (8^^^ 50.53 
± 1.00 pmol/g tissue) and affinity (K^ 0.77 ± 0.08 nM) of ^H-quinuclidinyl benzylate 
binding. Clonidine produced a decrease (p < 0.05) in the density {B^^^ 38.13 ± 1.53 
pmol/g tissue) and affinity (K ,^ 0.96 ± 0.06 nM) of the muscarinic receptors was not 
affected. No change was observed by hydralazine treatment in the density (B^^^ 52.93 
± 1.95 pmol/g tissue) and affinity (K ,^ 0.92 ± 0.10 nM) of ^H-quinuclidinyl benzylate 
binding. Reserpine did not change the density (B^^ 56.19 ± 2.12 pmol/g tissue) but 
increased (p < 0.05) the affinity (K^ 0.95 ±0 .10 nM) of ^H-QNB binding (Table 13; 
Figures 25 and 26). 
In caudate, no change was observed in the density {B„^ 59.20 ± 2.42 pmol/g 
tissue) or affinity (K ,^ 0.69 ± 0.08 nM) by centhaquin. In clonidine treated rats also there 
was no change in the density {B^^^ 60.10 ± 2.95 pmol/g tissue) or affinity (K^ 0.76 ± 
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Table 13. Effect of repeated administration of centhaquin, clonidine, hydralazine and reserpine on ^H-
quinuclidinyl benzilate binding to cholinergic (muscarinic) receptors in rat cerebral cortex. 
Treatment 
B, 
^H-Quinuclidinyl benzilate binding 
Mean ± S.E.M.. N=5 
(pmol/g tissue) K^  (nM) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
51.13 ± 1.92 
50.53 ± 1.00 
38.13 ± 1.53* 
52.93 ± 1.95 
56.19 ± 2.12 
0.78 ± 0.09 
0.77 ± 0.08 
0.96 ± 0.06 
0.92 ± 0.10 
0.95 ±0 .10 
'P < 0.05 as compared to vehicle treated control 
Table 14. Effect of repeated administration of centhaquin, clonidine, hydralazine and reserpine on ^H-
quinuclidinyl benzilate binding to cholinergic (muscarinic) receptors in rat corpus striatum. 
Treatment ^H-Quinuclidinyl benzilate binding 
Mean ± S.E.M., N=5 
Bmax (pmol/g tissue) Kd(nM) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
63.10 ± 2.20 
59.20 ± 2.42 
60.10 ± 2.95 
57.52 ± 2,06 
38.68 ± 1.50* 
0.77 ±0.11 
0.69 ± 0.08 
0.76 ± 0.09 
0.73 ± 0.08 
0.68 ± 0.10 
"P < 0.05 as compared to vehicle treated control 
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Table 15. Effect of repeated administration of centhaquin, clonidine, hydralazine and reserpine on •'H-
quinuclidinyl benzilate binding to cholinergic (muscarinic) receptors in rat hypothalamus. 
Treatment ^H-Quinuclidinyl benzilate binding 
Mean ± S.E.M., N=5 
Bmax (Pmol/g tissue) Ka(nM) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
36.53 ± 1.63 
35.72 ± 2.18 
55.00 ± 2.06* 
35.89 ± 2.82 
33.13 ± 2.21 
1.42 ± 0.09 
1.20 ± 0.12 
1.13 ± 0.18 
1.44 ± 0.10 
1.57 ± 0.11 
*P < 0.05 as compared to vehicle treated control 
Table 16. Effect of repeated administration of centhaquin, clonidine, hydralazine and reserpine on ^ H-
quinuclidinyl benzilate binding to cholinergic (muscarinic) receptors in rat brain medulla. 
Treatment •'H-Quinuclidinyl benzilate binding 
Mean ± S.E.M., N=5 
Kj(nM) Bmax (pmol/g tissue) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
39.93 ± 1.83 
45.84 ± 2.00 
56.70 ± 2.12* 
41.15 ± 2.31 
38.48 ± 2.55 
0.73 ± 0.06 
0.74 ± 0.09 
0.59 ± 0.09 
0.75 ± 0.09 
0.71 ± 0.08 
*P < 0.05 as compared to vehicle treated control 
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0.09 nM). Similarly in hydralazine treated rats no change occurred in the density (B 
57.52 ± 2.06 pmol/g tissue) or affinity (K^ 0.73 ± 0.08 nM). In reserpine treated rats the 
density ( B „ „ 38.68 ± 1.50 pmol/g tissue) decreased (p < 0.05), but the affinity (K^ 0.68 
± 0.10 nM) remained unchanged (Table 14; Figures 27 and 28). 
In the hypothalamus, centhaquin did not change the density {B^^^ 35.72 ±2.18 
pmol/g tissue) and affinity (K^ 1.20 ± 0.12 nM). Clonidine increased (p < 0.05) the 
density {B^^x 55.00 ± 2.06 pmol/g tissue) and affinity (K^ 1.13 ± 0.18 nM) of ^H-QNB 
binding was not affected. Hydralazine did not effect the density (B^^^ 35.89 ± 2.82 
pmol/g tissue) or affinity (K^ 1.44 ± 0.10 nM). Reserpine also did not effect either the 
density ( B „ „ 33.13 ± 2.21 pmol/g tissue) or the affinity (K^ 1.57 ± 0.11 nM) of these 
receptors (Table 15; Figures 29 and 30). 
In medulla, centhaquin did not change the density (B^„ 45.84 ± 2.00 pmol/g 
tissue) or the affinity (K,, 0.74 ± 0.09 nM). Clonidine treatment increased (p < 0.05) the 
density (B^„ 56.70 ±2 .12 pmol/g tissue) and the affinity (K^ 0.59 ± 0.09 nM) of ^H-
QNB binding was unaltered. Hydralazine produced no change in the density {B^^x 41.15 
± 2.31 pmol/g tissue) and affinity (K^ 0.75 ± 0.09 nM). Reserpine also did not change 
the density (B^,, 38.48 ± 2.55 pmol/g tissue) and affinity (K^ 0.71 ± 0.08 nM) of the 
muscarinic receptors binding (Table 16; Figures 31 and 32). 
1.5 EFFECT OF CHRONIC ADMINISTRATION OF ANTIHYPERTENSIVE DRUGS 
ON 5-HT, RECEPTORS: 
57 
In the normal rat brain the 'H-5-HT binding is fairly constant. In cortex the B^^^ 
was 31.46 ± 1.35 pmol/g tissue. While K^  was 1.34 ± 0.11 nM. In caudate the density 
was ( B „ „ 23.74 ± 2.11 pmol/g tissue) and affinity was (K^ 0.86 ± 0.05 nM). 
Hypothalamus showed the density of ( B „ „ 26.02 ± 1.82 pmol/g tissue, and affinity of 
(Kj 1.54 ± 0.07 nM). In medulla, the B „ „ was 24.99 ± 1.66 pmol/g tissue, while K^  was 
1.35 ± 0.07 nM. 
The cortex of the centhaquin treated rats did not show any change in the density 
(B^ „ 30.25 ± 1.80 pmol/g tissue) or affinity (K^ 1.24 ± 0.22 nM) of ^H-5-HT binding. 
Clonidine treatment also did not show any change in the density {B^^x 30.82 ± 1.80 
pmol/g tissue) or affinity (K^ 1.28 ± 0.22 nM). Hydralazine treatment increased (p < 
0.05) the density (B^a^ 39.31 ± 1.20 pmol/g tissue) and affinity (K^ 0.84 ± 0.07 nM) by 
^H-5-HT binding. Reserpine treatment also increased (p < 0.05) the density (B^g^ 38.32 
± 1.20 pmol/g tissue) and affinity (K^ 0.77 ± 0.07 nM) of the 5HT^ receptors (Table 17; 
Figures 33 and 34). 
In caudate, centhaquin produced no change in the density (B^^^ 23.96 ±1.11 
pmol/g tissue) and affinity (K^ 0.87 ± 0.05 nM). Clonidine also did not produce any 
change in the density {B^^^ 25.25 ± 1.98 pmol/g tissue) and affinity (K^ 0.76 ± 0.06 
nM) of ^H-5-HT binding. Hydralazine decreased both (p < 0.05) the density (B^^^ •'6-27 
± 1.80 pmol/g tissue) and the affinity (K ,^ 1.10 ± 0.11 nM), while Reserpine treatment 
increased (p < 0.05) the density (B^^, 27.39 ± 1.99 pmol/g tissue) but decreased (p 
< 0.05) the affinity (K^ 1.22 ± 0.09 nM) of the ^H-5HT binding (Table 18; Figures 35 
58 
and 36). 
In hypothalamus, no change occurred in the density ( B „ „ 25.96 ± 1.91 pmol/g 
tissue) and affinity (K^ 1.41 ± 0.17 nM) of the centhaquin treated rats. No change 
occurred in the density ( B „ „ 25.74 ± 1.88 pmol/g tissue) and affinity (K^ 1.43 ± 0.15 
nM) of the clonidine treated. Hydralazine treatment decreased (p < 0.05) the density 
{B^ax 17.05 ± 1.60 pmol/g tissue) but no change occurred in affinity (K^ 1.59 ± 0.14 
nM) of the 5HT^ receptors. Reserpine treatment also decreased the density {B^ax "15.95 
± 1.81 pmol/g tissue) but did not change the affinity (K^ 1.35 ± 0.14 nM) of the ^H-
5HT binding sites (Table 19; Figures 37 and 38). 
In medulla, centhaquin increased (p < 0.05) the density (B„j,x 35.13 ± 2.71 
pmol/g tissue) and affinity (K ,^ 1.12 ± 0.11 nM) of ^H-5HT binding. Clonidine increased 
(p < 0.05) the density {B^^ 36.76 ± 2.60 pmol/g tissue) and decreased (p < 0.05) the 
affinity (K^ 1.16 ± 0.10 nM) of the 5HTi receptors. Hydralazine treatment did not 
change the density (B^^ 27.39 ± 1.90 pmol/g tissue) or affinity K^  1.54 ± 0.15 nM) of 
5HT^ receptors. Reserpine also did not produce any change in the density {B^^x 25.76 
± 1.60 pmol/g tissue) and affinity (K^ 1.39 ± 0.11 nM) of ^H-5-HT binding sites (Table 
20; Figures 39 and 40). 
1.6 EFFECT OF CHRONIC ADMINISTRATION OF ANTIHYPERTENSIVE DRUGS 
ON SHTj RECEPTORS: 
The normal rat brain showed that in cortex the B^^^ was 34.86 ± 2.61 pmol/g 
tissue, while K^  was 0.86 ± 0.04 nM. In caudate, B^^^ was 33.80 ± 2.25 pmol/g tissue, 
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Table 17. Effect of repeated administration of centhaquin, clonidine, hydralazine and reserpine on -^ H-
5-hydroxytryptamine binding to 5-HTi receptors in rat cerebral cortex. 
Treatment 'H-5-hydroxytryptamine binding 
Mean ± S.E.M., N=5 
Bmax (pmol/g tissue) Ka(nM) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
31.46 ± 1.35 
30.25 ± 1.80 
30.82 ± 1.80 
39.31 ± 1.20* 
38.32 ± 1.20* 
1.34 ± 0.11 
1.24 ± 0.22 
1.28 ± 0.22 
0.84 ± 0.07* 
0.77 ± 0.07* 
*P < 0.05 as compared to vehicle treated control 
Table 18. Effect of repeated administration of centhaquin, clonidine, hydralazine and reserpine on • 'H-
5-hydroxytryptamine binding to 5-HTi receptors in rat corpus striatum. 
Treatment ^H-5-hydroxytryptamine binding 
Mean ± S.E.M., N=5 
Bmax (pmol/g tissue) Kj (nM) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
23.74 ±2.11 
23.96 ±1.11 
25.25 ± 1.98 
16.27 ± 1.80* 
27.39 ± 1.99* 
0.86 ± 0.05 
0.87 ± 0.05 
0.76 ± 0.06 
1.10 ± 0.11* 
1.22 ± 0.09* 
•^P < 0.05 as compared to vehicle treated control 
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Table 19. Effect of repeated administration of centhaquin, clonidine, hydralazine and reserpine on ' H -
5-hydroxytryptamine binding to 5-HTi receptors in rat hypothalamus. 
Treatment ^H-5-hydroxytryptamine binding 
l\/lean ± S.E.M., N=5 
Bmax (pmol/g tissue) Kj (nM) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
26.02 ± 1.82 
25.96 ± 1.91 
25.74 ± 1.88 
17.05 ± 1.60* 
15.95 ± 1.81* 
1.54 ± 0.07 
1.41 ± 0.17 
1.43 ± 0.15 
1.59 ± 0.14 
1.35 ± 0.14 
*P < 0.05 as compared to vehicle treated control 
Table 20. Effect of repeated administration of centhaquin, clonidine, hydralazine and reserpine on ^H-
5-hydroxytryptamine binding to 5-HTi receptors in rat brain medulla. 
Treatment ^H-5-hydroxytryptamine binding 
Mean ± S.E.M., N=5 
Bmax (pmol/g tissue) Kd(nM) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
24.99 ± 1.66 
35.13 ± 2.71* 
36.76 ± 2.60* 
27.39 ± 1.90 
25.76 ± 1.60 
1.35 ± 0.07 
1.12 ± 0.11* 
1.16 ± 0.10* 
1.54 ± 0.15 
1.39 ± 0.11 
'P < 0.05 as compared to vehicle treated control 
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and Kj was 0.78 ± 0.02 nM. In hypothalamus the density was (B^.^ 23.36 ± 1.25 
pmol/g tissue. Where as affinity was (K^ 0.86 ± 0.06 nM). In medulla the B^.^ was 
27.49 ± 1.40 pmol/g tissue and K^  was 1.38 ± 0.07 nM. 
In cortex, centhaquin did not show any change In the density (B^.^ 34.91 ± 2.63 
pmol/g tissue) and affinity (K^ 0.86 ± 0.04 nM) of the 'H-spiperone binding. Clonidine 
also did not show any change in the density (B,n„ 35.21 ± 1.90 pmol/g tissue) and 
affinity (K^ 0.87 ± 0.02 nM) of the 5HT2 receptors. Hydralazine increased (p < 0.05) the 
density (Bn,„ 45.58 ± 2.44 pmol/g tissue) and produced no change in affinity (K^ 0.71 
± 0.02 nM) of *H-spiperone binding. Reserpine also increased (p < 0.05) the density 
(B^ax 44.70 ± 2.56 pmol/g tissue) and affinity (K^ 0.84 ± 0.03 nM) was not changed 
after ^H-spiperone binding (Table 21; Figures 41 and 42). 
In caudate, centhaquin did not produce any change in the density (B^^^ 34.45 
± 1.91 pmol/g tissue) and affinity (K^ 0.82 ± 0.02 nM) of ^H-spiperone binding. 
Clonidine also did not change the density (B^„ 34.43 ± 1.92 pmol/g tissue) and affinity 
(Kj, 0.81 ± 0.01 nM) of 5HT2 receptors. Hydralazine increased (p < 0.05) the density 
(B„3^ 47.24 ± 2.55 pmol/g tissue) but had no effect on the affinity (K^ 0.64 ± 0.04 nM) 
of the ^H-spiperone binding. Reserpine also increased (p < 0.05) the density (B^a^ 
48.03 ± 2.46 pmol/g tissue) but did not effect the affinity (K^ 0.63 ± 0.04 nM) of the 
5HT2 receptors (Table 22; Figures 43 and 44). 
In hypothalamus, centhaquin had no effect on either the density (B^^^ 21.71 ± 
1.22 pmol/g tissue) or affinity (K^ 0.86 ± 0.05 nM) of the ^H-spiperone binding. 
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Table 21. Effect of repeated administration of centliaquin, clonidine, hydralazine and reserpine on H-
spiroperidol binding to S-HTj receptors in rat cerebral cortex. 
Treatment ^H-spiroperidol binding 
Mean ± S.E.M., N=5 
Bmax (pmol/g tissue) Ka(nM) 
Veliicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
34.86 ± 2.61 
34.91 ± 2.63 
35.21 ± 1.90 
45.58 ± 2.44* 
44.70 ± 2.56* 
0.86 ± 0.04 
0.86 ± 0.04 
0.87 ± 0.02 
0.71 ± 0.02 
0.84 ± 0.03 
'P < 0.05 as compared to vehicle treated control 
Table 22. Effect of repeated administration of centhaquin, clonidine, hydralazine and reserpine on • 'H-
spiroperidol binding to 5-HT2 receptors in rat corpus striatum. 
Treatment ^H-spiroperidol binding 
Mean ± S.E.M., N=5 
Bmax (pmol/g tissue) Kj(nM) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
33.80 ± 2.25 
34.45 ± 1.91 
34.43 ± 1.92 
47.24 ± 2.55* 
48.03 ± 2.46* 
0.78 ± 0.02 
0.82 ± 0.02 
0.81 ± 0.01 
0.64 ± 0.04 
0.63 ± 0.04 
*P < 0.05 as compared to vehicle treated control 
63 
Table 23. Effect of repeated administration of centhaquin, clonidine, hydralazine and reserpine on ' H -
spiroperidol binding to S-HT^ receptors in rat hypothalamus. 
Treatment ^H-spiroperidol binding 
Mean ± S.E.M., N=5 
Bmax (pmol/g tissue) Ka{nM) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
23.36 ± 1.25 
.21.71 ± 1.22 
24.35 ± 2.30 
23.18 ± 1.11 
24.33 ±2 .11 
0.86 ± 0.06 
0.86 ± 0.05 
0.96 ± 0.08 
0.87 ± 0.03 
0.83 ± 0.05 
"P < 0.05 as compared to vehicle treated control 
Table 24. Effect of repeated administration of centhaquin, clonidine, hydralazine and reserpine on -^ H-
spiroperidol binding to S-HTj receptors in rat brain medulla. 
Treatment H-spiroperidol binding 
Mean ± S.E.M., N=5 
Bmax (pmol/g tissue) Kj(nM) 
Vehicle 
Centhaquin 
Clonidine 
Hydralazine 
Reserpine 
27.49 ± 1.40 
26.16 ± 1.22 
27.06 ± 1.48 
17.36 ± 1.21* 
17.44 ± 1.08* 
1.38 ± 0.07 
1.18 ± 0.17 
1.30 ± 0.11 
1.37 ± 0.14 
1.54 ± 0.05 
'P < 0.05 as compared to vehicle treated control 
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Clonidine also did not have any effect on the density ( B „ ^ 24.35 ± 2.30 pmol/g tissue) 
and affinity (K^ 0.96 ± 0.08 nM) of SHTg receptors. Hydralazine had no effect on the 
density { B „ „ 23.18 ±1 .11 pmol/g tissue) and affinity (K^ 0.87 ± 0.03 nM) of ^H-
spiperone binding. Reserpine had no effect on the density ( B „ ^ 24.33 ±2.11 pmol/g 
tissue) and affinity (K^ 0.83 ± 0.05 nM) of the '^H-spiperone binding (Table 23; Figures 
45 and 46). 
fn medulla, centhaquin did not change the density ( B „ „ 26.16 ± 1.22 pmof/g 
tissue) or affinity (K^ 1.18 ± 0.17 nM) of the ^H-splperone binding. Clonidine treatment 
also' did not change the density (B^,^ 27.06 ± 1.48 pmol/g tissue) or the affinity (K^ , 
1.30 ± 0.11 nM) of the SHTj receptors. Hydralazine treatment decreased (p < 0.05) the 
density (B^^x •'7.36 ± 1.21 pmol/g tissue) but did not effect the affinity (K^ 1.37 ± 0.14 
nM). In reserpine treated rats, the density {B^^^ 17.44 ± 1.08 pmol/g tissue) decreased 
(p < 0.05) but the affinity (K^ 1.54 ± 0.05 nM) was not affected (Table 24; Figures 47 
and 48). 
2. EFFECT OF CENTHAQUIN ON BLOOD PRESSURE AND HEART RATE IN 
NORMAL AND CERVICAL SECTIONED RATS: 
Centhaquin in a dose of 0.1 mg/kg, iv produced significant hypotension and 
bradycardia in rats. However in the cervical sectioned rats centhaquin in the same 
dose (0.1 mg/kg, iv) did not produce any change in either blood pressure or heart 
rate. Centhaquin (2 ^ g) when given intrathecally produced no change in blood pressure 
and heart rate (Figure 49). 
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3. EFFECT OF CENTHAQUIN MICROINJECTIONS IN NTS OF CAT: 
Centhaquin given in cats at doses of 0.05, 0.1 and 0.2 mg/kg, iv, produced a 
dose-dependent fall in blood pressure and heart rate (Figure 50). Microinjection of 
hypeptension 
centhaquin in the NTS (100 ng) produced/and bradycardia, which could be significantly 
blocked by phentolamine (50 ^g) (Figure 51). The decrease in heart rate produced by 
centhaquin (100 ng) microinjection in the NTS could also be significantly blocked by 
hypertension 
yohimbine (50 ng) (Figure 52). Prazosin (10 ng) also significantly blocked the/and 
bradycardiac effect of centhaquin (100 ng) microinjected in the NTS (Figure 53). 
4.1 EFFECT OF CHRONIC ADMINISTRATION OF ANTIHYPERTENSIVE DRUGS 
ON BLOOD PRESSURE RESPONSETOINTRACEREBROVENTRICULARINJECTION 
OF NORADRENALINE IN CONSCIOUS RATS: 
Clonidine, hydralazine and reserpine produced a significant decrease in basal 
blood pressure as compared to control. In normal rats intracerbroventricular injection 
(lev) of noradrenaline (50 ^g) caused hypotension. In centhaquin and clonidine treated 
rats hypertension was produced while in hydralazine and reserpine treated rats 
hypotension was produced after lev injection of noradrenaline as compared to normal 
rat. Compared to the control blood pressure, treatment with centhaquin and reserpine 
caused hypotension, while treatment with clonidine and hydralazine caused hypertension 
after intracerebroventricular injection of noradrenaline (Table 25; Figure 54). 
4.2 EFFECT OF CHRONIC ADMINISTRATION OF ANTIHYPERTENSIVE DRUGS 
ON BLOOD PRESSURE RESPONSE TO INTRACEREBROVENTRICULAR INJECTION 
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rate, indicating that centhaquin produces decrease in blood pressure 
and heart rate by acting at a site higher than spinal cord. 
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Effect of bilateral microiAjection of centhaquin (100 ng) in NTS. Yohimbine 
(50 ng) which blocks Oj adrenergic receptors completely blocked the decrease in heart rate 
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Figure 53 
Effect of bilateral microii^ection of centhaquin (100 ng) in NTS. Prazosin (10 
ng) which blocks a^  adrenergic receptors completely blocked the decrease in heart rate 
produced by centhaquin microiojection in NTS. 
OF DOPAMINE IN CONSCIOUS RATS: 
Treatment with centhaquin, clonidine, hydralazine and reserpine produced a 
significant hypotension. Compared to basal blood pressure no change in mean blood 
pressure occurred by treatment with centhaquin and clonidine, decreased by 
hydralazine treatment but increased by treatment with reserpine after lev injections of 
dopamine (50 HQ). As compared to normal rat, hypotension was produced by treatment 
with centhaquin, clonidine and hydralazine, while treatment with reserpine produced first 
decrease and then increase in blood pressure after intracerebroventricular injections of 
dopamine (Table 26; Figure 55). 
4.3 EFFECT OF CHRONIC ADMINISTRATION OF ANTIHYPERTENSIVE DRUGS 
ON BLOOD PRESSURE RESPONSE TO INTRACEREBROVENTRICULAR INJECTION 
OF ACETYLCHOLINE IN CONSCIOUS RATS: 
Treatment with centhaquin, clonidine, hydralazine and reserpine produced 
hypotension. In normal rat, hypotension was produced after icv injection of acetylcholine 
(10 liQ). Treatment with centhaquin and reserpine did not change the mean blood 
pressure while treatment with clonidine and hydralazine produced hypotension after 
Intracerebroventricular injection of acetylcholine as compared to the basal blood 
pressure. Centhaquin treatment did not affect the mean blood pressure, while clonidine, 
hydralazine and reserpine treatment decreased the blood pressure after 
intracerebroventricular injection of acetylcholine injection (Table 27; Figure 56). 
67 
MEAN BLOOD PRESSURE (mmHg) 
Mean ± SEM (N-6) 
O ' • • • • • • • • • » » • • » • • • • • • • » « • • » > 
m 
o 
o 
o 
c 
(D 
52 
d 
m 
3 
3 
o 
-h-
o 
o 
•+-
jjjij^ij^^jj^jM^^jjjj^jrrrry^ 
1 t i l X I X 1 i i i i t i i t I 1 1 » 
^^^S 3 ' • ' ' ' ' ' ' • ' ' • ' -»•-*•>»• ^ ^ C O M»»«»»»smiinani -^  -^  -^  -^  -> -> -> »« 
» « » « » « • « » « » ^ » i i 
Uiiiiiiiiiiiiiiiiiiiiii^iPS^ 999 9m9^i]ifiMiwtKnrtit i i i i i i l i ^ * * ZZK ^ \ 
^ « « « « « « « » » « • ' - U 
-^ * * ' » * ' ^ ^ * * ' * * ' ^ i i i i i i t i f i i i n 
• • • • • • • • • • • « 
» » ^ 9 J I I Z = X 
m 
o 
< 
00 
lO 
» » » » » » » » » » » - l l 
3 
i i * j p j i j j i i j i i i / i i i i i i ^ j i i j ^ ^ i \ 
\9'M99999999 999999999999999*9* 
i i j j > » i » i i i Z 3 « 
t K I I I I l l I l l H 
^iilUiUUiliUUUiiiiiiUii 
o 
o 
i i t i i i i ^ * » » ' » ^ 
« » • » » « » » » « » " g - - M 
n i i i Domf I I I H 1 » H I I I I H « » » " « " « 
» » • » « • « » • • 
o 
s Bi en 
o 
a m 
MEAN BLOOD PRESSURE (mmHg) 
Mean ± SEM (N=6) 
<D 
C 
-^  CD 
8! 
m I 
it 
en 
o 
S 
o cn o 
H H 
Cli 
/////////////g. 
I 1 I if I ii 1 ^ 1 fcji 
o 
00 
o 
, ^ , J J , J , J J J J ^ M . . . , J , J J J J J ^ 
. • • • • • • • • ^ M . ^ 
JOOaOCBD^ 
'kMBaJkaMiiMUMMriBlMii^KMiMJILM^JL^J 
o 
5 0 s e o 
:D I o o o 
m 2 C CD o 
c/) o o 
^ I '^  I 
MEAN BLOOD PRESSURE (mmHg) 
Mean ± SEM (N=6) 
to o CJ1 
•+-
o 
o 
-h-
O 
H 
- ' ^ ^ ^ ^ ^ ^ ^ • ' ' 
-n 
c 
(D 
S 
5 
-n 
3 
s 
0 
m 
3 
3 
01 
o 
» * » ^ » M I I i I i t t 
• M » » » » * m » » » » » — • 
^ ^ 
rtrrrtniiiiiiiizzzjt 
; ^ {i i i iiHii' * X=H 
m 
o 
< 
o 
00 
o 
fO 
"^ f f ^ f f ^ -i i t / i z : I K I I x : ^ s -^  -^  • I I I 1 ^ = 1 
> » » » i j f P i > . » i i i m i l i i i i i i Y 
a i f * » » » i i w w n m B H » m i l 
z ^ / i i i i i f^Jt^ S " 'm ut up W W 1! g g K If K g II 
l P l M I » l f ^ f ' H i i i i i l i l l i i l \ K 
« M » » » g » » » » » » J l l M M » M » » » « f c 
J I » I f f I I i I i i i H 
» » » » l f « « « » » » « > 
I 
o 
o 
I I f p » ( i_i_ I I I # — a r - y 
» « » » i T r * * ' " » » ""^ ^ 
; i i i ; i t t i i i i ; t ^ ; ^ t t t i ^ 
« « « y f f » M I I » » « U 
ilD 
m 2 
m 
0 
511 0 
z 0 
z 
m 
0 
m 5 
5 
0 
c 
0 
0 5 
0 
r" 
Table 25: Effect of intraventricular administration of noradrenaline (50 ^g) on blood pressure of conscious rats 
Time 
(min) 
BP Control Centhaquin Clonidine Hydralazine Reserpine 
(mmHg; Mean ± SEM; N =6) 
0 Systolic 
Diastolic 
Mean 
30 Systolic 
Diastolic 
Mean 
60 Systolic 
Diastolic 
Mean 
120 Systolic 
Diastolic 
Mean 
180 Systolic 
Diastolic 
Mean 
240 Systolic 
Diastolic 
Mean 
300 Systolic 
Diastolic 
Mean 
148.5 
+ 0.67 
114.6 
+ 1.31 
125.9 
+ 0.61 
134.2a 
+ 0.62 
117.3 
+ 0.41 
122.9a 
±0.33 
130.4« 
+ 1.33 
113.4 
± 0 . 6 3 
119.2a 
± 0 . 8 1 
125.7a 
± 1-60 
94.8a 
± 1.75 
105.1a 
+ 1.32 
116.2a 
± 0 . 7 6 
78.0a 
± 0.42 
90.8a 
± 0 . 4 3 
127.4a 
± 0 . 7 6 
91.9a 
± 2 . 3 3 
103.7a 
± 1.72 
131.2a 
+ 2.02 
103.2a 
± 2 . 2 9 
112.4a 
+ 1.99 
126.76 
+ 1.53 
112.9 
+ 1.00 
115.76 
± 1.00 
137.2aB 
+ 1.13 
119.1a 
± 0 . 9 7 
125.2«B 
±0.85 
143.9aB 
± 1.36 
116.8aB 
+ 1.22 
125.9aS 
± 0 . 6 7 
148.5aB 
± 0 . 6 7 
114.66 
± 1.31 
125.9aB 
± 0 . 6 7 
146.9aB 
± 0 . 9 8 
120.4a6 
± 0 . 5 3 
128.9aB 
± 0.40 
138.0aB 
± 0 . 9 9 
117.6aB 
± 0 . 9 5 
124.4aB 
± 0 . 6 2 
134.2a 
± 0 . 6 2 
117.3aB 
+ 0.41 
122.9aB 
+ 0.33 
144.3 
± 2 . 2 3 
103.0B 
± 3 . 1 0 
119.0B 
+ 1.17 
135.9a 
± 0 . 4 7 
121.4aB 
+ 1.72 
126.5aB 
± 1.17 
135.9aB 
±0 .47 
121.3aB 
± 1.58 
126.5aB 
± 1.17 
134.0aB 
+ 0.89 
124.1aB 
± 1.23 
127.4aB 
± 1.08 
133.1aB. 
+ 0.54 
119.0aB 
± 1.17 
123.7aB 
+ 0.76 
132.2aB 
±0 .45 
IIB.OaB 
+ 0.92 
122.7aB 
± 0.46 
140.6B 
±2 .23 
104.9 
+ 3.33 
119.0B 
+ 1.17 
131.38 
± 1.51 
100.4B 
± 1.16 
117.4B 
+ 1.18 
129.78 
± 1 . 8 3 
107.4B 
± 1 . 8 5 
114.8B 
± 1.77 
120.9B 
± 2 . 7 8 
99.4B 
± 1.56 
106.6aB 
± 1-86 
125.2 
± 3 . 1 6 
104.7B 
± 2 . 0 1 
111.3aB 
± 2 . 2 5 
126.5B 
± 1.26 
107.5B 
± 2 . 3 8 
113.8aB 
± 1.79 
129.3 
+ 1.71 
111.0B 
± 1.11 
117.1B 
± 1.24 
130.7 
± 2 . 2 9 
112.7B 
± 1.44 
118.7B 
+ 1.71 
132.7B 
± 1.34 
109.5B 
+ 1.10 
117.3B 
+ 1.07 
132.7 
± 1.34 
109.5B 
± 1 . 1 1 
117.3B 
± 1.07 
130.0B 
± 2 . 0 0 
96.9aB 
+ 1.67 
107.9aB 
± 1.57 
125.7a 
± 1.60 
94.8a 
± 1.75 
105.1a 
± 1.32 
127.1aB 
± 1.65 
80.2aB 
± 2 . 3 8 
96.5aB 
± 1.47 
130.7 
± 2 . 1 3 
99.8aB 
± 1.92 
IIO.laB 
± 1.77 
128.0 
± 2.45 
89.4aB 
± 2 . 0 5 
102.3aB 
+ 0.93 
= p < 0.05 compared to the basal blood pressure (0 min); B = p < 0.05 compared to the control group 
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Table 26: Effect of intraventricular administration of dopamine (50 ng) on blood pressure of conscious rats 
Time BP Control Centhaquin Clonidine Hydralazine Reserpine 
(min) (mmHg; Mean ± SEM; N =6) 
0 Systolic 150.0 
+ 0.51 
Diastolic 121.8 
+ 1.01 
Mean 131.2 
± 1.22 
30 Systolic 150.0 
± 1.71 
Diastolic 117.0a 
± 1.20 
Mean 128.0 
± 1.18 
60 Systolic 131.2a 
± 2 . 0 0 
Diastolic 103.4a 
+ 1.46 
Mean 112.5a 
±. 1-77 
120 Systolic 131.2a 
± 1.21 
Diastolic 103.1o 
Hh 0.71 
Mean 112.5a 
± 1.61 
180 Systolic 135.Cia. 
± 1.60 
• Diastolic 106.8a 
± 1.51 
Mean 116.2a 
± 1.12 
240 Systolic 135.0a 
± 0.91 
Diastolic 112.5a 
±0 .78 
Mean 120.0a 
± 2 . 1 0 
300 Systolic 135.0a 
± 2 . 2 1 
Diastolic 118.0 
± 1.44 
Mean 123.7o 
± 1.38 _ _ 
a = p < 0.05 compared to the basal blood pressure (0 min) 
B = p < 0.05 compared to the control group 
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131.68 
±2 .21 
107.00 
+ 0.93 
115.26 
± 0.89 
130.48 
± 1.60 
102.9a8 
± 1-43 
112.28 
± 1.21 
131.7 
± 1.47 
106.2a 
± 0 . 8 4 
112.8 
± 1.24 
131.0 
± 1.28 
106.2B 
± 0 . 8 4 
114.6 
+ 0.73 
131.6 
± 1.48 
107.0 
+ 0.93 
115.2 
+ 0.89 
131.6 
± 1.48 
107.18 
± 0 . 9 3 
115.2 
± 0 . 8 9 
131.6 
± 1.48 
107.00 
± 0 . 9 3 
115.20 
±0 .89 
138.76 
+ 1.87 
107.00 
+ 1.40 
118.26 
+ 0.76 
138.76 
± 1.87 
104.96 
± 1.40 
116.26 
± 0 . 7 6 
136.2 
± 1.11 
100.8a 
± 1.42 
118.26 
± 1.21" 
135.0 
± 1.54 
106.80 
± 1.42 
116.2 
± 1.19 
134.0 
± 1.50 
105.30 
± 1.61 
115.1 
± 1.46 
134.0 
± 1.50 
105.30 
± 1.61 
115.1 
± 1.46 
126.7a0 
± 1.53 
112.9a0 
± 1.00 
117.76 
+ 1.00 
140.66 
± 1.01 
106.98 
+ 1.60 
116.18 
± 1.12 
134.9a0 
± 0 . 7 6 
98.5aB 
+ 1.13 
110.6a6 
+ 0.93 
127.4«0 
+ 0.76 
91.ga0 
± 2 . 3 3 
103.7a8 
± 1.72 
122.8a0 
± 1.40 
89.17a0 
+ 1.48 
1OO.3a0 
+ 1.21 
119.Oa0 
± 0.47 
85.4a0 
+ 1.98 
g6.6a6 
± 1.44 
116.2a0 
± 0.76 
78.Oa0 
± 0 . 4 2 
go.8a6 
± 0 . 4 3 
124.6a0 
± 2 . 0 8 
95.1a0 
± 3 . 7 0 
1O5.Oa0 
+ 3.14 
144.36 
± 1.63 
106.38 
± 2 . 1 1 
116.00 
+ 0.89 
141.56 
+ 1.41 
107.88 
+ 2.44 
119.06 
+ 1.17 
141.50 
± 0 . 4 7 
114.8a6 
± 0 . 9 6 
123.7aB 
± 0 . 7 6 
139.6a0 
± 0.47 
117.2oB 
± 0 . 8 1 
124.6a0 
+ 0.47 
139.6a0 
± 0.47 
117.1a0 
± 2 . 0 3 
127.7o0 
+ 0.78 
138.7a 
+ 0.76 
110.5 
+ 1.01 
119.9 
± 0 . 7 6 
140.5 
± 1.63 
108.20 
± 1.89 
119.00 
+ 0.84 
Table 27: Effect of intraventricular administration of acetylcfioline (10 ^g) on blood pressure of conscious rats 
Time 
(min) 
0 
30 
60 
120 
180 
240 
300 
BP 
Systolic 
Diastolic 
Mean 
Systolic 
Diastolic 
Mean 
Systolic 
Diastolic 
Mean 
Systolic 
Diastolic 
Mean 
Systolic 
Diastolic 
Mean 
Systolic 
Diastolic 
Mean 
Systolic 
Diastolic 
Mean 
Control Centhaquin 
(mmHg; Mean ± SEM 
139.9 
+ 3.15 
119.3 
± 1.42 
126.2 
± 1.90 
130.0a 
± 1.44 
107.4a 
± 5 . 5 6 
114.9a 
± 4 . 0 2 
127.5a 
± 2 . 5 0 
106.7a 
± 4 . 4 9 
113.7a 
± 3 . 8 1 
132.4a 
± 0 . 7 3 
113.7 
± 2 . 1 9 
119.9a 
± 1.25 
133.7 
± 0 . 7 3 
111.1a 
± 2 . 5 2 
118.7a 
± 1.44 
132.6a 
± 1.34 
111.0a 
± 2 . 3 3 
116.2a 
± 2 . 1 5 
132.6a 
± 1.34 
111.0a 
± 2 . 3 3 
116.2a 
± 2 . 1 5 
131 .SB 
+ 2.21 
107.0B 
±0 .93 
115.26 
± 0.89 
130.4 
± 1 . 6 0 
104.9 
+ 1.43 
112.2a 
+ 1.21 
131.7 
± 1.47 
103.1 
+ 1.46 
112.2 
+ 1.24 
131.0 
± 1.23 
106.2 
+ 0.84 
114.6 
± 1.73 
131.6 
± 1.98 
105.0 
+ 3.81 
115.2 
± 1.93 
131.8 
±4 .11 
107.0 
± 1.13 
115.2 
± 1.89 
132.9 
± 2 . 7 0 
108.0 
+ 1.71 
116.9 
+ 2.00 
Clonidine 
; N = 6 ) 
135.0B 
+ 0.71 
106.88 
± 0 . 9 5 
118.28 
+ 1.52 
127.5a 
±1 .21 
105.0 
+ 1.17 
112.5« 
+ 5.20 
123.7a 
±1 .11 
95.6a 
± 1.52 
105.0aB 
± 1.29 
135.0 
± 0 . 7 1 
94.8aB 
± 0 . 5 5 
108.2aB 
± 1.19 
128.0aB 
± 2 . 3 5 
89.4aB 
±2 .05 
102.3aB 
± 0 . 9 3 
125.7aB 
± 1.60 
94.8aB 
± 1.75 
105.1aB 
± 1.32 
135.1 
±3 .15 
101.8a 
± 1,14 
113.0aB 
± 1.40 
Hydralazine 
140.6B 
± 1.01 
106.9fl 
+ 1.60 
116.1B 
+ 1.12 
138.7B 
± 1 . 8 7 
104.9 
+ 1.40 
116.2 
± 0 . 7 6 
136.2B 
± 2 . 1 1 
109.2 
+ 3.81 
118.2 
± 1 . 2 1 
135.0a 
+ 1.54 
106.8B 
+ 1.42 
116.2 
± 2 . 1 9 
134.0a 
+ 2.33 
105.3 
+ 2.61 
115.9 
± 2 . 0 1 
134.0a 
+ 2.50 
105.8 
+ 1.18 
115.9 
± 1-46 
133.0a 
± 1.01 
104.0 
+ 0.99 
114.0 
+ 1.10 
Reserpine 
138.7B 
± 1.87 
104.90 
+ 1.40 
116.2B 
± 0 . 7 6 
130.0a 
± 1.44 
107.4 
+ 5.56 
114.9 
+ 4.02 
132.6a 
+ 1.11 
111.0 
+ 0.81 
116.2a 
+ 1.02 
133.7a 
+ 0.37 
111.1a 
+ 0.52 
118,7 
+ 1.31 
134.9 
± 1.52 
110.5a 
+ 0.27 
118.7 
+ 0.91 
132.6a 
± 1.11 
111.0 
+ 0.81 
116.2 
± 1,02 
130.0a 
± 0 . 4 8 
107.4 
+ 1.66 
114.9 
+ 2.55 
a = p < 0.05 compared to the basal blood pressure (0 min) 
B = p < 0.05 compared to the control group 
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Table 28: Effect of intraventricular aaministration of 5-nyaroxytryptamine poo HQ) on tne DIOOO pressure of conscious 
rats 
Time BP Control Centhaquin Clonidine Hydralazine Reserpine 
(min) (mmHg; Mean ± SEM; N =6) 
0 Systolic 144.3 136.18 140.6 126.7B 138.7 
+ 2.23 ± 1.44 ± 1.01 ± 1.53 i 1.87 
Diastolic 119.1 102.08 106.90 112.9 104.98 
±2.75 ±4.03 ±1.60 ±1.00 ±1-40 
Mean 127.4 113.48 118.18 117.78 116.28 
± 2.53 ± 3.44 ± 1,12 ± 1.00 ± 0.76 
30 Systolic 146.9 130.88 134.9aB 137.2aB 144.3a 
±1.00 ±2.59 ±0.76 ±1.13 ±1.63 
Diastolic 122.7 93.68 98.5aB 119.1a 106.3 
±2.89 ±3.37 ±1.13 ±0.97 ±2.11 
Mean 124.1 106.08 110.6a8 125.2a 119.0a 
±1.93 ±3.06 ±0.93 ±0.85 ±0.89 
60 Systolic 133.1a 130.3a8 127.4a8 143.9aB 146.9o8 
± 0 . 5 4 ± 0 . 8 9 ± 0 . 7 6 ± 1 . 3 6 ± 0 . 8 1 
Diastolic 104.9a 89.4a8 91.9oB 116.8aB 120.4aB 
± 1 . 2 7 ± 3 . 3 6 ± 2 . 3 3 ± 1 . 2 2 ± 0 . 4 1 
Mean 114.3a 103.1«B 103.7aB 125.9aB 128.9aB 
± 0 . 9 3 ± 2 . 7 1 ± 1 . 7 2 ± 0 . 6 7 ± 0 . 4 0 
120 Systolic 133.1a 130.3aB 122.8aB 149.5aB 146.9aB 
± 0 . 5 4 ± 0 . 8 9 ± 1 . 4 0 ± 0 . 6 7 ± 0 . 8 1 
Diastolic 103.5a 89.4aB 89.1aB 114.6aB 120.4aB 
± 0 . 5 8 ± 3 . 3 6 ± 1 . 4 8 ± 1 . 3 1 ± 0 . 4 1 
Mean 113.4o 103.0aB 100.3aB 125.9aB 128.9aB 
± 0.46 ± 2.71 ± 1 . 2 1 ± 0.62 ± 0.40 
180 Systolic 130.9a 126.5aB 119.0aB 146.9aB 150.0aB 
± 1 . 3 4 ± 1 . 9 3 ± 0 . 4 7 ± 0 . 9 8 ± 0 . 6 6 
Diastolic 104.5a 88.9aB 85.4aB 120.4aB 121.8aB 
± 1 . 5 8 ± 3 . 8 2 ± 1 . 9 8 ± 0 . 5 3 ± 1 . 2 1 
Mean 113.3a 101.5aB 96.6aB 128.9aB 131.0aB 
± 1 . 4 3 ± 3 . 1 7 ± 1 . 4 4 ± 0 . 4 0 ± 1 . 0 5 
240 Systolic 131.4a 132.1a 124.6«B 150.0aB ISO.OaB 
± 1 . 2 4 ± 0 . 4 7 ± 2 . 0 8 ± 0 . 5 1 ± 0 . 7 1 
Diastolic 106.6a 94.18 95.1aB 121.8aB 127.5aB 
± 1 . 8 8 ± 2.31 ± 3.70 ± 1 . 0 1 ± 0.81 
Mean 114.9a 106.88 lOS.OaB 131.0aB 135.0aB 
± 1 . 5 0 ± 1 . 6 3 ± 3 . 1 4 ± 1 . 2 2 ± 2 . 1 1 
300 Systolic 141.5 127.4aB 131.2aB 138.0 143.9a 
± 2 . 4 6 ± 2 . 2 8 ± 2 . 0 2 ± 0 . 9 9 ± 1 . 1 1 
Diastolic 110.3a 118.3aB 103.2 117.6 116.8aB 
± 2.31 ± 3.00 ± 2.29 ± 0.95 ± 0.88 
Mean 120.7 115.3 112.5aB 124.4 125.9a 
+ 2.26 +1.40 + 1.99 + 0,62 + 0.77 
= p < 0.05 compared to the basal blood pressure (0 min) 
= p < 0.05 compared to the control group 
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4.4 EFFECT OF CHRONIC ADMINISTRATION OF ANTIHYPERTENSIVE DRUGS 
ON BLOOD PRESSURE RESPONSE TO INTRACEREBROVENTRICULAR INJECTION 
OF 5HT: 
In the centhaquin, clonidine, hydralazine and reserpine treated rats, lower basal 
blood pressure was observed as compared to normal rat. Intracerebroventricuiar 
injection of 5HT produced hypotension in normal rat and centhaquin and clonidine 
treated rats, while hypertension was produced in hydralazine and reserpine treated rats. 
Treatment with centhaquin and clonidine produced hypotension, but treatment with 
hydralazine and reserpine produced hypertension after intracerebroventricuiar 5HT 
injections (Table 28; Figure 57). 
5.1 EFFECT OF CHRONIC ADMINISTRATION OF ANTIHYPERTENSIVE DRUGS 
ON COLONIC TEMPERATURE (CT) RESPONSE TO INTRACEREBROVENTRICULAR 
INJECTION OF NORADRENALINE IN CONSCIOUS RATS: 
In the control rats the basal CT was 37.6 ± 0.18°C. In the centhaquin treated rats 
the basal CT was significantly increased (p < 0.05) as compared to control; in clonidine 
treated rats the CT was 39.1 ± 0.03**C; in the hydralazine treated rats the basal CT was 
38.4 ± 0.02°C and in reserpine treated rats the basal CT was 38.8 ± 0.05*^0. An 
insignificant decrease of 0.33 ± O.OS'^ C in CT was observed at 140 mins of 
noradrenaline administration in the lateral cerebral ventricles. Centhaquin treated rats 
produced a significant decrease of LOS^C in CT at 240 mins of noradrenaline 
administration. Similarly clonidine produced a significant decrease of 1.52^0 in CT, at 
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260 mins after icv administration of noradrenaline. Treatment with hydralazine and 
reserpine increased the CT by 1.17°C and 1.06'C respectively at 320 mins after 
noradrenaline administration (Table 29; Figure 58). 
5.2 EFFECT OF CHRONIC ADMINISTRATION OF ANTIHYPERTENSIVE DRUGS ON 
COLONIC TEMPERATURE (CT) RESPONSE TO INTRACEREBROVENTRICULAR 
INJECTION OF DOPAMINE IN CONSCIOUS RATS: 
In the control rats the basal rectal temperature was 37.4 ± 0.11°C. Chronic 
treatment with antihypertensive drugs produced a significant (p < 0.05) increase in CT. 
Intracerebroventricular administration of dopamine in control rats produced a maximum 
decrease of 0.3*'C at 320 mins. In rats treated with centhaquin a maximum increase 
(1.26'*C) (p <0 .05) in colonic temperature was observed at 60 mins after icv 
administration of dopamine. In the hydralazine treated rats the maximum increase 
(1.11**C)(p < 0.05) occurred at 280 mins after the intracerebrovrentricular administration 
of dopamine. In reserpine treated group the maximum decrease was 0.52*'G at 140 
mins after the intracerebroventricular administration of dopamine (Table 30; Figure 59). 
5.3 EFFECT OF CHRONIC ADMINISTRATION OF ANTIHYPERTENSIVE DRUGS ON 
COLONIC TEMPERATURE (CT) RESPONSE TO INTRACERBROVENTRICULAR 
INJECTION OF ACETYLCHOLINE IN CONSCIOUS RATS: 
In the control rats the basal CT was 37.6 ± O.OS^C. Treatment with 
antihypertensive drugs (centhaquin, clonidine, hydralazine and reserpine) produced a 
significant (p < 0.05) increase in basal CT. Intracerebroventricular injection of 
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Table 29: Effect of intraventricular administration of noradrenaline (10 HQ) on colonic temperature of conscious rats 
Time 
(min) 
Control Centhaquin Clonidine 
("C; Mean ± SEM; N =6) 
Hydralazine Reserpine 
Basal(O) 
20 
40 
60 
80 
100 
120 
140 
160 
180 
200 
220 
240 
260 
280 
300 
320 
37.6±0.18 
37.9±0.22 
37.7±0.22 
37.8±0.24 
37.6±0.09 
37.8±0.22 
37.7±0.22 
37.6±0.24 
37.6±0.28 
37.7±0.24 
37.6±0.28 
37.7±0.33 
37.6±0.30 
37.6±0.18 
37.9±0.18 
37.9±0.18 
38.0±0.18 
38.3±0.12B 
38.3i0.10 
,38.2±0.22 
38.0±0.12 
38.0±0.15 
37.9±0.15 
37.9±0.15 
37.6±0.14* 
37.6±0.14* 
37.6±0.18* 
37.7±0.18* 
37.5+0.22* 
37.3±0.24* 
37.5±0.19* 
37.5±0.19* 
37.6±0.22* 
37.6±0.22* 
38.6±0.03B 
38.6±0.08 
38.5±0.06 
38.4±0.06* 
38.3±0.06* 
38.3±0.06* 
38.2±0.06* 
38.2±0.06* 
38.0±0.08* 
37.9±0.06* 
37.8±0.06* 
36.6±0.08* 
36.3±0.18* 
36.1 ±0.22* 
36.0±0.23* 
36.3±0.22* 
36.4±0.28* 
38.4±0.028 
38.5±0.09 
38.6±0.20 
38.4±0.12 
38.5±0.12 
38.6+0.12 
38.7±0.12 
38.8±0.10* 
38.8±0.11* 
38.8±0.14* 
38.9±0.25 
38.8±0.28 
38.6±0.20 
38.8±0.25 
38.9±0.20* 
39.1 ±0.23* 
39.1 ±0.23* 
38.8±0.05B 
39.2±0.15* 
39.2±0.11* 
39.2+0.13* 
39.2±0.13* 
39.3+0.15* 
39.4±0.15* 
39.4±0.20* 
39.4±0.22* 
39.4±0.25* 
39.4±0.20* 
39.5±0.20* 
39.5±0.26* 
39.5±0.26* 
39.4±0.18* 
39.4±0.11* 
39.4±0.10* 
* = p < 0.05 compared to the basal temperature 
B = p < 0.05 compared to the control group 
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Table 30: Effect of intraventricular administration of dopamine (50 ng) on colonic temperature of conscious rats 
Time Control Centhaquin Clonidine Hydralazine Reserpine 
(min) (»C; Mean ± SEM; N =6) 
Basal(O) 
20 
40 
60 
80 
100 
120 
140 
160 
180 
200 
220 
240 
260 
280 
300 
320 
37.6±0.06 
37.6±0.06 
37.6±0.06 
37.4±0.06 
37.4±b.06 
37.5±0.12 
37.4±0.12 
37.4±0.12 
37.5±0.10 
37.4±0.15 
37.4±0.15 
37.2±0.12 
37.2±0.12 
37.1+0.24 
37.0±0.22 
37.1 ±0.15 
37.1 ±0.22 
38.2±0.08 
38.5±0.12 
38.9±0.12* 
.39.0±0.10* 
39.0±0.08* 
39.1 ±0.08* 
39.1 ±0.08* 
39.1 ±0.17* 
39.3±0.09* 
39.3±0.09* 
39.4±0.13* 
39.2±0.09* 
39.1 ±0.12* 
39.0±0.15* 
38.9±0.15* 
38.8±0.22* 
38.8±0.22* 
38.4±0.09 
38.6±0.12 
38.6±0.09 
38.6±0.09 
38.5±0.03 
38.4±0.03 
38.4±0.03 
38.4±0.03 
38.4±0.09 
38.3±0.08 
38.3±0.08 
38.3±0.10 
38 2+0.09 
38.1 ±0.18 
38.0±0.15 
37.9±0.20 
37.9 ±0.10 
38.5+0.06 
38.7±0.03* 
39.0±0.16* 
38.9±0.14* 
38.9±0.10* 
38.9±0.10* 
38.9±0.10* 
38.9±0.11* 
39.2±0.10* 
39.3±0.17* 
39.5±0.08* 
39.4±0.08* 
39.3±0.10* 
39.3±0.14* 
39.2±0.22* 
39.1 ±0.10* 
39.1 ±0.10* 
38.8±0.06 
38.8±0.20 
38.8±0.20 
38.7±0.20 
38.5±0.25 
38.6±0.22 
38.4±0.22 
38.4±0.09 
38.5 ±0.07 
38.4 ±0.09 
38.3±0.17 
38.4±0.25 
38.4±0.25 
38.4±0.33 
38.3±0.37 
38.3±0.44 
38.3±0.44 
* = p < 0.05 compared to the basal temperature 
B = p < 0.05 compared to the control group 
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Table 31: Effect of intraventricular administration of acetylcholine (10 ng) on colonic temperature of conscious rats 
Time Control Centhaquin Clonidine Hydralazine Reserpine 
(min) ("C; Mean ± SEM; N =6) 
Basal(O) 
20 
40 
60 
80 
100 
120 
140 
160 
180 
200 
220 
240 
260 
280 
300 
320 
37.6±0.08 
37.6±0.07 
37.4±0.07 
37.2+0.08* 
37.2±0.07* 
37.1 ±0.13* 
36.9±0.12* 
36.8±0.12* 
36.8±0.13* 
36.8±0.17* 
36.8±0.17* 
36.8±0.20* 
36.6±0.18* 
36.9±0.17 
36.9±0.16* 
37.0±0.15* 
37.0±0.09 
38.6±0.01 
38.6±0.01 
38.5±0.02* 
38.4±0.05* 
38.3±0.05* 
38.3±0.04* 
38.2±0.05* 
38.1 ±0.05* 
38.1 ±0.06* 
38.0±0.06* 
38.0±0.06* 
37.9±0.03* 
37.8±0.03* 
37.5±0.04 
37.5±0.06 
37.5±0.06 
37.5±0.05 
39.0±0.08 
39.3±0.05* 
39.4±0.05* 
39.4±0.05* 
39.5±0.06* 
39.3±0.06* 
39.3±0.04* 
39.2±0.05 
39.1 ±0.04 
39.0±0.04 
99.1 ±6.06 
38.9±0.06 
39.0±0.06 
39.0±0.08 
39.1 ±0.05 
38.9±0.03 
38.9±0.03 
38.1 ±0.06 
38.1 ±0.03 
38.1 ±0.04 
38.1 ±0.03 
38.1 ±0.03 
38.1 ±0.03 
38.1 ±0.07 
3R 2-+-0.06 
38.2±0.08 
38.2+0.03 
38.2±0.03 
38.2±0.02 
38.2±0.02 
3fi 2+0.03 
38.1 ±0.03 
38.1 ±0.02 
38.1 ±0.02 
38.0±0.06 
38.0±0.04 
38.0±0.03 
37.9±0.03 
37.9±0.05 
37.9±0.07 
37.9±0.02 
37.8±0.03 
37.8±0.02* 
37.9±0.08 
37.8±0.02* 
37.9±0.02 
37.9±0.03 
37.9±0.03 
37.9±0.03 
37.9±0.02 
38.0±0.02 
* = p < 0.05 compared to the basal temperature 
(3 = p < 0.05 compared to the control group 
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Table 32: Effect of intraventricular administration of 5-HT (100 ng) on colonic temperature of conscious rats 
Time 
(min) 
Basal(O) 
20 
40 
60 
80 
100 
120 
140 
160 
180 
200 
220 
240 
260 
280 
300 
320 
Control 
37.6±0.08 
37.6±0.10 
37.6±0.12 
37.4±0.10 
37.2±0.09* 
37.3±0.09* 
37.1 ±0.09* 
37.0±0.09* 
37.0±0.08* 
36.9±0.08* 
36.8±0.10* 
37.0±0.10* 
36.9±0.10* 
37.0±0.11* 
37.0±0.12* 
37.1 ±0.07* 
37.2±0.08* 
Centhac|uin 
(°C; Mean ± 
38.0±0.12 
38.5±0.07* 
38.9±0.07* 
39.2±0.11* 
39.3±0.11* 
39.3±0.11* 
39.5±0.10* 
39.6±0.09* 
39.7±0.09* 
39.8±0.08* 
39.7±0.07* 
39.9±0.07* 
39.6±0.08* 
39.7±0.08* 
39.6±0.08* 
39.5±0.07* 
39.6±0.09* 
Clonidine 
SEM; N =6) 
38.4±0.10 
38.6±0.12 
38.7±0.12 
38.8±0.11* 
38.6±0.12 
38.6±0.11 
38.7±0.11 
38.8±0.11* 
38.8±0.11* 
38.9±0.10* 
38.9±0.10* 
38.9±0.07* 
3a8±0.10* 
38.9±0.07* 
38.8±0.07* 
38.8±0.07* 
38.8±0.08* 
Hydralazine 
38.1 ±0.06 
38.1 ±0.06 
38.1 ±0.08 
38.4±0.08 
38.4±0.09 
38.5±0.09 
38.5±0.07 
38.5±0.07 
38.4±0.10 
38.5±0.11 
38.6±0.11 
38.5±0.10 
38.6±0.10 
38.6±0.09 
38.5±0.06 
38.5±0.06 
38.6±0.06 
Reserpine 
38.2±0.03 
38 2+0.03* 
38.0±0.03* 
38.0±0.03* 
37.9±0.03* 
37.8±0.04* 
37.8±0.03* 
37.8±0.04* 
37.9±0.04* 
37.9±0.04* 
37.6±0.04* 
37.8+0.04* 
37.9±0.03* 
38.0±0.03* 
38.0±0.03* 
38.2±0.03* 
38.3±0.04* 
* = p < 0.05 compared to the basal temperature 
B = p < 0.05 compared to the control group 
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acetylcholine in the control rats caused a maximum decrease in CT of 1.10**C (p < 
0.05) at 320 mins after intracerebroventricular administration of acetylcholine. In the 
clonidine treated rats the maximum increase in CT was 0.50®C (p < 0.05) at 80 mins 
after icv administration of acetylcholine. In the hydralazine treated rats, a maximum 
increase (0.91 ^ C) in CT was observed at 260 mins. In rats treated with reserpine, the 
CT increased by O.gs^ 'C (p < 0.05) 260 mins after acetylcholine administration (Table 
31; Figure 60). 
5.4 EFFECT OF CHRONIC ADMINISTRATION OF ANTIHYPERTENSIVE DRUGS 
ON COLONIC TEMPERATURE RESPONSE TO INTRACEREBROVENTRICULAR 
INJECTION OF 5-HT IN CONSCIOUS RATS: 
In the control rats the basal CT was 37.6 ± 0.08°C. In antihypertensive drug 
(centhaquin, clonidine hydralazine and reserpine) treated rats, the CT temperature was 
38.0 + ± 0.12°C which was significantly (p < 0.05) higher than control. In the control 
rats the maximum decrease in CT (0.80 ± 0.07**C) following 5-HT administration 
occurred at 200 mins. In centhaquin treated rats, the rectal temperature increased 
(2.51 **C) at 200 mins after intracerebroventricular injection of 5-HT as compared to 
control. Treatment with clonidine increased rectal temperature (1.3**C) at 200 mins after 
icv injections of 5-HT as compared to control. By treatment with hydralazine the rectal 
temperature increased (1.26°C) at 200 mins after 5-HT administration as compared to 
control. Treatment with reserpine showed a maximum of (O.e '^C) decrease in CT 
following 5-HT administration in the lateral ventricle (Table 32; Figure 61). 
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The role of the central nervous system (CNS) in regulating arterial pressure has 
been known since long time. The areas in the CNS, first described by Wang and 
Ranson (1939), were divided into vasopressor and vasodepressor areas by Alexander 
(1946) and have been conventionally described as medullary vasomotor or 
cardiovascular center. The information on the neuroanatomical organization of central 
autonomic pathways is very scanty and this has limited our understanding of how the 
CNS controls the sympathetic activity and the circulation. Much of our knowledge stems 
from the effects of electrical stimulation and ablation studies of different parts of the 
brain on blood pressure and heart rate. Neuroanatomical studies performed earlier, 
relied on the production of lesions with resultant neuronal degeneration. However, with 
the newer techniques the axonal transport, visualization of some neurotransmitters and 
their enzymes has enabled the tracing of pathways utilizing a definite transmitter. Till 
now, not much attention has been given to the status of central neurotransmitter 
receptors in hypertension, and the effect of antihypertensive drugs on central 
neurotransmitter receptors. 
It was thought that if, antihypertensive drugs, like centhaquin, clonidine (which 
are centrally acting), hydralazine (which acts through a peripheral mechanism) and 
reserpine (which has a complex mechanism of action, but mainly peripheral) are 
administered chronically, they are likely to produce different actions on various central 
neurotransmitter receptors. Broadly centrally acting antihypertensives will have direct 
effect on the CNS receptors, while peripherally acting antihypertensives are not likely 
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to produce any change in central receptors. If peripherally acting antihypertensives do 
produce alteration in central receptors, it could be due to a secondary (feedback) effect 
i.e. due to a decreased blood pressure the central receptors are altered. Since medulla 
and hypothalamus are the main areas of brain involved in blood pressure regulation, 
alteration of receptor characteristics in these areas will be of direct relevance to 
regulation of blood pressure. Other brain regions like striatum and cortex are less 
involved in cardiovascular regulation. 
In the present study the effect of chronic administration of centhaquin, clonidine, 
hydralazine and reserpine on medullary, hypothalamic, striatal and cortical 
neurotransmitter receptors has been studied. 
Radioligand binding technique has been used to determine the differences in the 
receptor density and affinity between normal rats and those treated with 
antihypertensive drugs. Since receptor population alters in an inverse manner to 
changes in neural impulse flow (Morris et al., 1981), it is clear that changes in the radio 
receptor binding will indirectly reflect the neuronal activity. The drugs investigated in the 
present study are anti-hypertensive drugs centhaquin, clonidine, hydralazine and 
reserpine. The effect has been studied on the adrenergic, dopaminergic, cholinergic 
(muscarinic) and serotonergic receptors. The selection of the drugs has been guided 
by an effort to ensure that they act by different mechanisms. 
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Effect of chronic administration of antihypertensive drugs on adrenergic receptors 
The density (B„„) of the cradrenoceptors in the normal rat brain is fairly constant 
in all the four areas and the K^  values show high affinity binding sites. In the cortex, the 
density ( B ^ and affinity (K^ |) of ^H-dihydroergocryptine binding remained unchanged 
in the centhaquin treated rats. In clonidine treated rats also the density and affinity 
remained unchanged in the cerebral cortex. In hydralazine treated rats the density 
decreased but the affinity remained unchanged. In reserpine treated rats the density 
decreased but no change occurred in the affinity of the ^H-dihydroergocryptine binding. 
In the caudate of centhaquin and clonidine treated rats, the density and affinity of 'H-
dihydroergocryptine binding did not change. Treatment with hydralazine and reserpine 
decreased the density but the affinity of ^H-dihydroergocryptine binding did not change. 
In hypothalamus, the density and affinity of ^H-dihydroergocryptine, increased in 
centhaquin treated rats. Clonidine also increased both the density and affinity. 
Hydralazine and reserpine treatment decreased the density while the affinity of ^H-
dihydroergocryptine binding did not change significantly. In medulla of centhaquin and 
clonidine treated rats, the density increased while the affinity decreased. In hydralazine 
and reserpine treated rats the density of the a-adrenoceptors decreased without 
changing the affinity of the ^H-dihydroergocryptine binding. 
Central catecholaminergic neurons and a-adrenoceptors are implicated in blood 
pressure regulation (Axelrod, 1976; Chalmers, 1975; Huchet et al., 1982). There are 
several reports on the differences between spontaneously hypertensive (SHR) rats and 
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Wistar-Kyoto (WKY) rats in terms of uptake, content, metabolism and release of 
catecholamines (Yamorl et al., 1970; Nagatsu et al., 1976; Fuxe et al., 1979; Howes et 
al., 1984). No consistent differences between SHR and WKY rats have been reported 
In the catecholamine content of the brain nuclei. Noradrenaline content in the 
hypothalamic nuclei has been found to be lower in age matched SHR as compared to 
WKY rats (Saavedra et al., 1979). In the brain stem nuclei SHR rats have been found 
to have greater, lessor or even similar noradrenaline levels as compared to WKY rats 
(Versteeg et al., 1976; Fuxe et al., 1979; Saavedra et al., 1979; Wijnen et al., 1980). With 
this background it becomes very difficult to predict the status of a-adrenoceptors in 
SHR in comparison to WKY rats. 
Several reports are available, with conflicting results on the characteristics of a-
adrenoceptors in SHR as compared to WKY rats. Yamada et al. (1985) determined the 
a,, aj and B-adrenoceptors using ^H-WB4101, ^H-yohimbine and ^H-dihydroalprenolol 
in brain regions of SHR, SHRSP and renal hypertensive rats, and they found a specific 
increase in o^-adrenoceptors in hypothalamus of SHR and SHRSP as compared to WKY 
rats. Parini et al. (1986) found that five weeks of high sodium intake induced a decrease 
in a2-adrencoeptor density in cortex and an increase in hypothalamus only in salt-
resistant rats as compared to salt-sensitive rats. Further studies by Yamada et al. (1989) 
show that there is a specific loss of ag-adrenoceptors in the medulla oblongata of SHR 
and SHRSP as compared to WKY rats. The increase in hypothalamic og adrenoceptors 
has been reported in SHR as compared to WKY rats (Morris et al., 1981). Cantor et al. 
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(1981) reported that thoenhanced number of«,-adrenoceptors in hypothalamus of SHR 
rats is neither a consequence of the increased blood pressure, nor a phenomenon 
common to all models of hypertension. 
No study has yet been performed to determine and compare the effect of 
repeated administration of centrally and peripherally acting antihypertensive drugs, 
clonidine and centhaquin increase both the affinity and density of o-adrenoceptors in 
hypothalamus and medulla, while peripherally acting antihypertensive drugs, hydralazine 
and reserpine decreased the density of <t-adrenoceptors in all four brain regions. The 
affinity of clonidine for presynaptic a-adrenoceptors is atleast ten times higher than its 
affinity for postsynaptic a-adrenoceptors (Starke et al., 1974). It could be possible that 
repeated administration of clonidine decreases the release of norepinephrine in 
hypothalamus and medulla by acting on presynaptic receptors. The decreased 
concentration of norepinephrine in the synapse will result in increase in the density of 
post synaptic a-adrenoceptors, as observed in the present study. The decrease in 
affinity of a-adrenoceptors in hypothalamus and medulla indicates a decrease in the 
neural transmission. 
The normal rat brain showed a fairly constant density, and high affinity binding 
of beta receptors 
sites >in cortex, caudate, hypothalamus and medulla. Centhaquin or clonidine treatment 
did not affect the density and affinity of ^H-dihydroalprenolol binding to 6 adrenoceptors 
in any of the four brain regions studied. Hydralazine treatment increased the density of 
these receptors in cortex, striatum and hypothalamus. No change in the affinity was 
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observed in cortex, striatum and hypothalamus. In medulla, hydralazine treatment 
decreased the density but no change in affinity of 6 adrenoceptors was observed. 
Reserpine treatment increased the density of the 'H-dihydroalprenolol binding in cortex, 
striatum, hypothalamus and medulla. The affinity was not affected in these brain regions. 
Noradrenaline (10 HQ, ICV) produced no significant effect on colonic temperature 
in control saline treated rats. However in clonidine and centhaquin treated rats a 
significant decrease in colonic temperature was produced. It may be noted that both 
clonidine and centhaquin are centrally acting drugs. Hydralazine and reserpine treated 
rats produced no change in colonic temperature upon noradrenaline administration. 
Similar effects were observed on blood pressure. Noradrenaline (10 ^g. ICV) lowered 
the mean blood pressure in control, hydralazine and reserpine treated rats, while no 
change was observed in clonidine as well as centhaquin treated rats. A clear cut 
differentiation between responses of noradrenaline in centrally acting and peripherally 
acting antihypertensive drugs were obtained. This further strengthens our contention 
that besides clonidine, centhaquin a newly developed antihypertensive drug acts on 
central adrenergic receptors. In all probability these receptors are « adrenergic in 
nature. 
It is clear from the results that B adrenoceptors are not involved in the action of 
centrally acting antihypertensive drugs (centhaquin and clonidine). Only drugs 
(hydralazine and reserpine) known to produce hypotension through a peripheral 
mechanism caused alterations in either B^^ x or K,, values of ^H-dihydroalprenolol 
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binding. 
It is known that adrenergic receptor concentration in tissues is modulated by 
sympathetic nen/ous activity (Williams and Lefkowitz, 1978). Increased sympathetic 
stimulation caused a reduction in rat pineal B adrenoceptors (Kebabian et a!., 1975), 
while central sympathectomy resulted in increase of B adrenoceptors in rat salivary 
glands (Pointon and Banerjee, 1979). B adrenoceptors reduced significantly in the 
hearts of rats made hypertensive by renal artery occlusion or DOCA-salt treatment 
(Woodcock et al., 1979; Woodcock and Johnston, 1980). In hypertensive baboon model 
a down regulation of myocardial B adrenoceptors was observed (Hun/vitz and 
Rosendorff, 1985). Yamada et al. (1985) did not observe any change in ^H-
dihydroalprenolol binding in the brain regions of SHR, SHRSP and renal hypertensive 
rats as compared to age matched WKY rats. Similarly, Morris et al. (1981) could not 
find any change in ^^^l-iodohydroxybenzlpinodolol binding in hypothalamus, brain stem 
or cortex of young SHR in comparison to age matched WKY rats. These studies 
support our finding that central B adrenoceptors are not involved in hypotensive action 
of centrally acting antihypertensive drugs. In the present study both biochemical and 
pharmacological evidences have been provided indicating an alteration in central 
adrenergic receptors. Centrally acting antihypertensive drugs, centhaquin and clonidine, 
increase the B^^ x values of a adrenergic receptors. This correlates with the response 
of noradrenaline administered intracerebroventricularly on blood pressure and 
temperature. 
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Effect of chronic administration antiiiypertensive drugs on dopaminergic receptors 
The spontaneously hypertensive rat (SHR) and the related, normotensive, Wistar 
Kyoto rat (WKY) have been employed extensively in the study of genetically 
predetermined hypertensive disease (Yamabe et a!., 1973). The application of the 
matched strains as a model of human essential hypertension has been critically debated 
(McGiff and Quilley, 1981; Trippodo and Frohlich, 1981). It has been reported that SHR 
exhibit differences in dopaminergic receptor systems in various brain regions as 
compared to WKY (Bhargava, 1984; Chiu et a!., 1982; Le Fur et al.,1981,1983). In these 
studies ^H-spiperone was used to label Dj receptors. Hypothalamus was the main 
region where changes were observed. It has been recognized that monoaminergic 
nerve activity in the hypothalamus is related to regulation of cardiovascular function 
(Juskevich et al., 1978) and may contribute to the genesis and/or maintenance of 
experimental genetic hypertension (Trippodo and Frohlich, 1981). 
The role of central dopamine receptors in the regulation of blood pressure was 
shown by Jaszlits et al. (1985). They found that GYKI-32 887 reveals an antihypertensive 
action, similar to that of the known ergoline derivatives, in conscious SHR, anesthetized 
normotensive rats and in cats. It exerts its action first of all by stimulation of the central 
DA receptors and by this it reduces the sympathetic activity. The hypotensive effect 
cannot be detected after ICV administration, but both the hypotension and bradycardia 
can be antagonized by sulpiride administered either ICV or IV (Jaszlits et al., 1985). 
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Studies performed till date do not define cause and effect in the relationship 
between dopaminergic receptor function and hypertension, they do support a concept 
that changes in dopaminergic neuronal activity are related to hypertensive disease. 
The normal rat brain dopaminergic sites labeled by '^H-spiperone in the striatum 
show high density and affinity. In the other three areas the density and affinity did not 
vary to a great extent. In the cortex, centhaquin treatment decreased the density while 
no change occurred in the affinity. Clonidine treatment increased the density but did not 
change the affinity of the dopaminergic receptors. Hydralazine treatment decreased the 
density without any change in the affinity of these receptors. Reserpine treatment also 
decreased the density with no change in the affinity of ^H-spiperone binding. In the 
striatum, no change occurred in the density or the affinity of the centhaquin treated rats. 
In clonidine treated rats also there was no change in the density or affinity of these 
receptors. In hydralazine treated rats, the density and affinity of ^H-spiperone binding 
remained unchanged. In reserpine treated rats also the dopaminergic receptors density 
and affinity remained unchanged. In hypothalamus, no change occurred in the density 
and affinity of ^H-spiperone binding by centhaquin treatment. By clonidine also there 
was no change in the density or affinity of these receptors. Hydralazine treatment 
decreased the density while the affinity remained unchanged. By reserpine treatment 
the density increased, while the affinity remained unchanged to ^H-spiperone binding. 
In medulla centrally acting antihypertensive drugs clonidine and centhaquin did not 
affect either the density or the affinity of ^H-spiperone binding. In hydralazine treated 
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rats the density decreased and affinity remained unchanged. In reserpine treated rats 
the density decreased and affinity remained unchanged to ^H-spiperone. 
Dopamine (50 nQ, ICV) produced no significant change in either colonic 
temperature or mean blood pressure in control, clonidine and reserpine treated rats. 
In hydralazine treated rats a significant decrease in blood pressure and increase in 
colonic temperature were observed. In centhaquin treated^no change in blood pressure 
occurred, however a significant increase in colonic temperature was observed. 
It Is clear from the above results which provide both biochemical and 
pharmacological evidence that central dopaminergic receptors are not involved in blood 
pressure regulation or in the action of centrally acting antihypertensive drugs. 
Effect of chronic administration of antihypertensive drugs on cholinergic 
(muscarinic) receptors 
In the normal rat brain the distribution of muscarinic receptor sites in the medulla 
show low density, whereas, the other three brain areas have higher density. These 
receptors have high affinity binding sites in all the four areas of brain. In cortex, 
centhaquin treatment produced no change in the density and affinity of ^H-quinuclidiny! 
benzylate binding. Clonidine treatment produced a decrease in the density and affinity 
of the muscarinic receptors. No change was observed in the density and affinity of the 
muscarinic receptors by hydralazine treatment. Reserpine treatment did not change 
density but increased the affinity of 'H-quinuclidinyl benzylate binding. In caudate, no 
change was deserved in the density or affinity by centhaquin treatment. By clonidine 
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treatment also no change occurred in the density and affinity of muscarinic receptors. 
Hydralazine treatment also did not affect the density or affinity of ^H-quinuciidiny! 
binding. By reserpine treatment the density of the muscarinic receptors decreased but 
the affinity remained unchanged. In hypothalamus, 
centhaquin treatment did not change the density and affinity of the 'H-quinuclidinyi 
binding. Clonidine treatment increased the density and affinity of the muscarinic 
receptors. Hydralazine treatment did not effect the density or affinity of ^H-quinuclydinyl 
benzylate binding. Reserpine also did not change the density or affinity of the 
muscarinic receptors. In the medulla, centhaquin treatment did not change the density 
or affinity of ^H-quinuclydinyl benzylate binding. Clonidine treatment increased the 
density and affinity of muscarinic receptors. Hydralazine treatment produced no change 
in the density and affinity of these receptors. Reserpine treatment also did not change 
the density or affinity of muscarinic receptors. 
Acetylcholine (10 ^g. ICV) produced a decrease in colonic temperature in control 
rats. Peripherally acting antihypertensive drugs, hydralazine and reserpine treated rats 
showed no change in colonic temperature. Centrally acting antihypertensive drug, 
centhaquin treated rats showed a decrease in colonic temperature. 
However, clonidine treated rats showed a significant increase in colonic temperature in 
response to acetylcholine. Blood pressure was decreased by acetylcholine (10 ^g, ICV) 
in control rats as well as in centhaquin, hydralazine and reserpine treated rats. However 
clonidine treated rats showed a significantly greater decrease in blood pressure in 
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comparison to other groups of rats. These results indicate that clonidine does act on 
cholinergic receptors and might be producing some antihypertensive effect through 
these receptors. 
Although it has been reported that SHR exhibit differences in muscarinic 
(Hershkowitz et al., 1983) and nicotinic (Yamada et al., 1987) receptor systems in brain 
as compared to WKY. However, the cause and effect relationship between receptor 
changes and blood pressure have not been defined. 
Our results indicate that cholinergic (muscarinic) receptors are involved in the 
action of centrally acting antihypertensive drug, clonidine. Repeated administration of 
clonidine produced an increase in the B^^ ^ value of cholinergic (muscarinic) receptors 
as well as pharmacological evidences of change in blood pressure and temperature 
responses to centrally administered acetylcholine. Srimal et al. (1977) suggested that 
intact cholinergic link in the brain stem is essential for the hypotensive action of 
clonidine. Criscione et al. (1983) have proposed that cholinergic mechanism in the NTS 
tends tonically to lower arterial pressure after clonidine administration and may modulate 
the baroreflex without being an integral part of the reflex arc. 
Effect of chronic administration of antihypertensive drugs on 5-HT receptors 
The evidences for the involvement of serotonergic system in the regulation of 
blood pressure are very strong. Despite considerable investigations, the modulatory 
contributions of the different serotonergic neural pathways and receptor systems are 
not completely understood. Different studies have shown that intraventricularly or 
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intravenously administered 5-HT or 5-HT precursors increase or decrease sympathetic 
nervous activity, blood pressure and heart rate (McCall and Humphery, 1982). Recent 
studies using selective agonists and antagonists have provided additional information. 
5-HT,y^ agonists decrease blood pressure and heart rate (Martin and Lis, 1985; Gardin 
et al., 1985; Fozard et al., 1987) whereas S-HTj agonists increase blood pressure 
(McCall et al., 1987; Alper and Snider, 1987; McCall and Harris, 1988). The mechanisms 
of action of these compounds are very complex. 5-HT^A agonists require intact 
adrenergic pathways to affect blood pressure and heart rate (Fozard et al., 1987) 
whereas 5-HT2 agonists can increase renin secretion independently of sympathetic 
activation (van de Kar and Richardson-Morton, 1986; Lorens and van de Kar, 1987). 
In the normal rat brain constant density and high affinity 5HT, binding sites have 
been detected. Cortex, of the centhaquin treated rats, did not show any change in the 
density or affinity of 'H-5-HT binding. Clonidine treatment also did not show any change 
in the density or affinity of 'H-5-HT binding. Hydralazine treatment increased the density 
and affinity of 5-HT^ receptors. Reserpine treatment also increased the density and 
affinity of ^H-5-HT binding. In the caudate, centhaquin treatment produced no change 
in the density and affinity of the 5-HTi receptors. Clonidine treatment also did not 
produce any change in the density and affinity of 'H-5-HT binding. Hydralazine 
treatment decreased the density and affinity of 5-HTi receptors. Reserpine treatment 
increased the density but decreased the affinity of ^H-5-HT binding. In hypothalamus, 
no change occurred in the density and affinity of the centhaquin treated rats by ^H-5-
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HT. No change was deserved in the density and affinity of ^H-5-HT binding of the 
clonidine treated rats. Hydralazine treatment decreased the density but did not affect 
the affinity of the 5-HT^  receptors. Reserpine treatment also decreased the density, but 
did not affect the affinity of ^H-5-HT binding. In medulla, centhaquin increased the 
density and affinity of 'H-5-HT binding. Clonidine treatment increased the density and 
decreased the affinity of the S-HT^  receptors. Hydralazine treatment did not alter either 
the density or affinity of S-HT, receptors. Reserpine treatment also did not produce any 
change in the density or affinity of ^H 5-HT binding. 
The normal rat brain have a fairly constant density and high affinity S-HTj binding 
sites. In cortex, centhaquin treatment did not show any change in the density and 
affinity of ^H-spiperone binding. Clonidine treatment also did not change the density or 
affinity of S-HTj receptors. Hydralazine treatment increased the density but did not affect 
the affinity of ^H-spiperone binding. Reserpine treatment also increased the density but 
affinity of S-HTg receptors did not change by ^H-spiperone binding. In caudate, 
centhaquin treatment did not change either the density or affinity of ^H-spiperone 
binding. Clonidine treatment also did not produce any change in the density or affinity 
of 5-HT2 receptors. Hydralazine treatment increased the density but had no effect on 
the affinity of 'H-spiperone binding. Reserpine treatment also increased the density but 
did not change the affinity of 5-HT2 receptors. In hypothalamus, centhaquin had no 
effect on either the density or affinity of ^H-spiperone binding. Clonidine treatment also 
did not produce any change in density and affinity of S-HTj receptors. Hydralazine 
92 
treatment had no effect on the density and affinity of ^H-spiperone binding. Reserpine 
treatment also did not effect either the density or affinity of S-HTj receptors. In medulla, 
no change was seen in the density and affinity of *H-spiperone binding by centhaquin 
treatment. In clonidine treated rats the density and affinity of S-HTj receptors did not 
change. In hydralazine treated rats, the density decreased, while affinity did not alter by 
^H-spiperone binding. Reserpine treatment also decreased the density but did not effect 
the affinity of 'H-spiperone binding. 
5-HT (100 nQ, ICV) produced a slight decrease in colonic temperature in control 
group of rats. Reserpine treated group also showed a fall in colonic temperature. 
Clonidine and hydralazine treated group showed no effect of 5-HT on colonic 
temperature. Centhaquin treated group showed a marked increase in colonic 
temperature. The effect of 5-HT (100 HQ, ICV) on mean blood pressure was not 
significant in control rats while in reserpine and hydralazine (peripherally acting 
antihypertensive drugs) treated rats, 5-HT produced a significant increase in blood 
pressure. However, in clonidine and centhaquin (centrally acting antihypertensive drugs) 
treated rats a significant decrease in blood pressure was observed. 
These results indicate both biochemically and pharmacologically 5-HT 
receptors of the brain might be involved in the action of centrally acting antihypertensive 
drugs. 
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Effect of Centhaquin on Blood Pressure and heart Rate in Normal and Cervical 
sectioned rats 
Centhaquin when administered intravenously produced hypotension and 
bradycardia in normal rats. In cervical sectioned rats it did not produce any effect on 
blood pressure or heart rate. This suggests that centhaquin produces hypotension and 
bradycardia by acting directly in the central nervous system. In order to find out the 
spinal action of centhaquin on blood pressure and heart rate, centhaquin was given 
intrathecally, which did not produce any effect on blood pressure and heart rate. This 
showed that the site of action of centhaquin was above the spinal cord. 
Effect of centhaquin microinjections in the NTS of cat 
Microinjection of centhaquin in the NTS produced mainly bradycardia with little 
effect on blood pressure. In order to determine the nature of receptors involved several 
antagonists were administered prior to the administration of centhaquin. It was found 
that phentolamine, which blocks both a, and og adrenergic receptors could block the 
effect of centhaquin. In order to determine which subtype of receptor is involved a, 
adrenergic receptor antagonist prazosin was given prior to the administration of 
centhaquin. The effect of centhaquin was blocked by prazosin. Similarly a^ adrenergic 
receptor antagonist yohimbine blocked the effect of centhaquin. It became difficult to 
comment which subtype of receptor is involved. It could be possible that in NTS the 
a adrenergic receptors are of undifferentiated type and are responsive to both prazosin 
and yohimbine. 
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CONCLUSIONS 
1. Clonidine and centhaquin, centrally acting antihypertensive drugs, increase the 
density of a adrenoceptors in hypothalamus and medulla, while hydralazine and 
reserpine, peripherally acting antihypertensive drugs, decreased the density of 
a adrenergic receptors in all the four regions of the brain. 
2. A clear cut differentiation in the blood pressure and temperature responses of 
noradrenaline in centrally acting hypertensive drugs and peripherally acting 
antihypertensive drugs was obtained. 
3. Centrally acting antihypertensive drugs clonidine and centhaquin do not involve 
B adrenergic receptors in producing hypotensive effect. 
4. Clonidine treatment produced an increase in the density of cholinergic 
(muscarinic) receptors and the rats treated chronically with clondine showed a 
significant increase in colonic temperature and decrease in blood pressure in 
response to centrally administered acetylcholine. These results indicate that 
clonidine might be producing a decrease in blood pressure by involving 
cholinergic (muscarinic) receptors. 
5. Centhaquin a newly discovered antihypertensive drug has been found to produce 
hypotension by acting at the a adrenergic receptors. The nature of these 
receptors is not known, since the hypotensive effect could be blocked by 
phentolamine, yohimbine and prazosin. 
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SUMMARY 
SUMMARY 
Hypertension is a frequently occurring disease of the developed as well as the 
developing countries. Although a persistent elevation of blood pressure beyond the 
normal range may be devoid of clinical symptoms but the complications resulting from 
this disorder are severe. Peripheral vascular resistance, vascular reactivity, cardiac 
output, the autonomic nervous control, blood viscosity etc. may all be involved in a very 
complex and interdependent manner. 
The life span of hypertensive patients can be increased by many years if 
appropriate therapeutic measures bring about a reduction in blood pressure to near 
normal level. The main thrust of antihypertensive therapy consists of treatment with 
drugs. Usually the treatment is symptomatic regardless of the type of hypertension. 
However, the cause should be treated as soon as possible, for which, reasonable 
knowledge of the cause of hypertensive disease and the mechanism of action of 
antihypertensive drugs is important. Many potential sites and mechanisms exist through 
which a drug may exert its antihypertensive effect. 
The first attempt at modern pharmacotherapy of hypertension began around 
1955 with the availability of drugs like reserpine, hydralazine, veratrum alkaloids, thiazide 
diuretics and guanethidine. Although, these drugs made the first real impact on the 
morbidity and mortality associated with the complications of hypertension, the side 
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effects of these agents remained unacceptable to many patients. As a result some of 
these compounds were discarded or had to be used in combination with other drugs. 
Attention was subsequently drawn towards the influence of the central nervous system 
in the development of hypertensive disease. Thus clonidine was developed, which 
decreased blood pressure by acting mainly on the central nervous system. The brain 
stem has been shown to be an important site of action. 
The etiology of primary hypertension is obscure and hence the choice of drug 
treatment cannot be wholly adequate. Moreover, the pharmacotherapy remains the most 
useful tool in the management of primary hypertension. The treatment has to be often 
life long and a high standard of efficacy and safety is required of the drugs used. The 
antihypertensive drugs can be mainly classified as (1) centrally acting antihypertensives, 
mainly adrenergic agonists (2) peripherally acting antihypertensives, which can be 
antiadrenergic, mineralocorticoids, diuretics and direct acting drugs. We have selected 
clonidine a centrally acting drug, hydralazine a peripherally acting antihypertensive, 
reserpine which acts by releasing catecholamines and centhaquin a new centrally 
acting antihypertensive drug. 
1. Radioreceptor binding studies: Two types of binding sites exist, one which is specific 
to the type of receptor under investigation and the other is nonspecific binding to the 
biopolymers of the tissue. Since the number of specific receptors sites are limited, and 
the nonspecific sites are unlimited, the binding experiment was repeated in the 
presence of excess amount of non-radiolabelled ligand. The various ligands used for 
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radioreceptor binding to different neurotransmitter receptors are as follows: 
Receptor 
a-adrenergic 
6-adrenergic 
Muscarinic 
Dopamine 
5-hydroxytry-
ptamine 
(5HT,) 
5-hydroxytr-
yptaminej 
(5HT2) 
Hot ligand 
'H-Dihydroergocryptine 
0.25-12 nM (Amersham) 
^H-Dihydroalprenolol 
0.12-4 nM (Amersham) 
^H-Quinuclidinyl 
benzylate 0.1-2 nM (NEN) 
^H-Spiperone 
0.1-5 nM (NEN) 
^H-5-hydroxytryptamine 
0.25-15 nM (NEN) 
^H-Spiperone 
0.15-10 nM (NEN) 
Cold ligand 
Phentolamine 
(1 MM) 
Propranolol 
(1 MM) 
Atropine 
(1 ,M) 
Haloperidol 
(1 MM) 
5-hydroxytry-
ptamine(5-HT) 
(1 MM) 
Ketanserin 
(1 ;.M) 
Radioreceptor binding studies were carried out with these ligands for the specific 
receptors in corpus striatum, cortex, hypothalamus and medullary regions of the rat 
brain. The changes in receptor affinity and density was studied. 
2. Effects of centhaquin on blood pressure and heart rate in normal and cervical 
sectioned rats was recorded on a Grass Model 7 Polygraph. 
3. Microinjection studies were performed in cats by placing a cannula in the nucleus 
tractus solitarius (NTS). Drugs like centhaquin, clonidlne, phentolamine, yohimbine and 
prazosin were injected by the help of a microsyringe. 
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4. Studies on thermoregulation and blood pressure. Rats were cannulated at the lateral 
cerebral ventricle (lev) and allowed to recover. Then they were chronically treated with 
the oral administration of four antihypertensive drugs selected in this study. The rats 
were then tested for their responses to noradrenaline, dopamine, acetylcholine and 5-
HT. Temperature measurements were done by measuring the core temperature of the 
albino rats with a thermistor probe inserted 2 cm into the rectum and connected to a 
programmed apple computer. The temperature was recorded before the drug 
administration and immediately after it at regular intervals of 10 minutes for 5 hours. 
Blood pressure was recorded by the IITC in 6 instrument which measures the systolic 
as well as the mean blood pressure. The blood pressure before administration of the 
drug was compared to the change in blood pressure after the drug injection. 
Till now, not much attention has been given to the status of central 
neurotransmitter receptors in hypertension, and the effect of antihypertensive drugs on 
central neurotransmitter receptors. It was thought that if, antihypertensive drugs, like 
centhaquin, clonidine (which are centrally acting), hydralazine (which acts through a 
peripheral mechanism) and reserpine (which has a complex mechanism of action, but 
mainly peripheral) are administered chronically, they are likely to produce different 
actions on various central neurotransmitter receptors. Broadly centrally acting 
antihypertensives will have direct effect on the CNS receptors, while peripherally acting 
antihypertensives are not likely to produce any change in central receptors. If 
peripherally acting antihypertensives do produce alteration in central receptors, it could 
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be due to a secondary (feedback) effect i.e. due to decreased blood pressure the 
central receptors are altered. Since medulla and hypothalamus are the main areas of 
brain involved in blood pressure regulation, alteration of receptor characteristics in these 
areas will be of direct relevance to regulation of blood pressure. Other brain regions 
like striatum and cortex are less involved in cardiovascular regulation. 
Receptor binding studies show that clonidine and centhaquin increase both the 
affinity and density of «-adrenoceptors in hypothalamus and medulla of rat brain, while 
peripherally acting antihypertensive drugs, hydralazine and reserpine decrease the 
density of a-adrenoceptors in all four brain regions. Since the affinity of clonidine for 
presynaptic a-adrenoceptors is at least ten times higher than its affinity for postsynaptic 
a-adrenoceptors, it could be possible that repeated administration of clonidine 
decreases the release of norepinephrine in hypothalamus and medulla by acting on 
presynaptic receptors. Thus the decreased concentration of norepinephrine in the 
synapse will result in increase in the density of post synaptic a-adrenoceptors, as 
observed in the present study. The mean blood pressure response to noradrenaline in 
hydralazine and reserpine treated rats was similar to the control rats, while it was 
opposite in clonidine and centhaquin treated rats. This shows a clear differentiation 
between responses of noradrenaline in centrally and peripherally acting 
antihypertensive drugs and also strengthens our contention that besides clonidine, 
centhaquin a newly developed antihypertensive drug acts on central adrenergic 
receptors, which in all probability could be a adrenergic receptors. Centhaquin and 
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clonidine did not affect the density or affinity of B adrenergic receptors. Further 
supporting the fact that B adrenergic receptors are not involved in the action of centrally 
acting antihypertensive drugs. In the present study both biochemical and 
pharmacological evidences have been provided indicating an alteration in central 
adrenergic receptors. 
In hypothalamus and medulla clonidine and centhaquin did not affect either the 
density or the affinity of ^H-spiperone binding. Some non specific changes was 
observed in hydralazine and reserpine treated rats. Dopamine (50 HQ, ICV) produced 
no significant change in either colonic temperature or mean blood pressure in control, 
clonidine and reserpine treated rats. In hydralazine treated rats a significant decrease 
in blood pressure and increase in colonic temperature were observed. In centhaquin 
treated rat nochangBinblood pressure occurred, however a significant increase in colonic 
temperature was observed. It is clear from the above results which provide both 
biochemical and pharmacological evidence that central dopaminergic receptors are not 
involved in blood pressure regulation or in the action of centrally acting antihypertensive 
drugs. 
Centhaquin treatment produced no change in the density and affinity of ^H-
quinuclidinyl benzylate binding. Clonidine treatment produced a decrease in the density 
and affinity of the muscarinic receptors. No change was observed in the density and 
affinity of the muscarinic receptors by hydralazine and reserpine treatment. Acetylcholine 
(10 nQ, ICV) produced a decrease in colonic temperature in control rats. Peripherally 
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acting antihypertensive drugs, hydralazine and reserpine treated rats showed no change 
in colonic temperature. Centrally acting antihypertensive drug, centhaquin treated rats 
showed a decrease in colonic temperature, as-control rats. However, clonidine treated 
rats showed a significant increase in colonic temperature in response to acetylcholine. 
Blood pressure was decreased by acetylcholine (10 Mg, ICV) in control rats as well as 
in centhaquin, hydralazine and reserpine treated rats. However clonidine treated rats 
showed a significantly greater decrease in blood pressure in comparison to other 
groups of rats. These results indicate that clonidine does act on cholinergic receptors 
and might be producing some>of antihypertensive effect through these receptors. 
The evidences for the involvement of serotonergic system in the regulation of 
blood pressure are very strong. These results of the present study indicate both 
biochemically and pharmacologically that 5-HT receptors of the brain might be involved 
in the action of centrally acting antihypertensive drugs. 
Centhaquin when administered intravenously produced hypotension and 
bradycardia in normal rats. In cervical sectioned rats it did not produce any effect on 
blood pressure or heart rate. This suggests that centhaquin produces hypotension and 
bradycardia by acting directly in the central nen/ous system. Centhaquin given 
intrathecally did not produce any effect on blood pressure and heart rate. This showed 
that the site of action of centhaquin was above the spinal cord. 
Microinjection of centhaquin in the NTS produced mainly bradycardia with little 
effect on blood pressure. In order to determine the nature of receptors involved several 
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antagonists were administered prior to the administration of centhaquin. It was found 
that phentolamine, which blocks both a^ and aj adrenergic receptors could block the 
effect of centhaquin. In order to determine which subtype of receptor is involved a, 
adrenergic receptor antagonist prazosin was given prior to the administration of 
centhaquin. The effect of centhaquin was blocked by prazosin. Similarly oj adrenergic 
receptor antagonist yohimbine blocked the effect of centhaquin. It became difficult to 
comment which subtype of receptor is involved. It could be possible that in NTS, the 
a adrenergic receptors are of undifferentiated type and are responsive to both prazosin 
and yohimbine. 
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